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Designing new drug delivery systems requires tight control of drug release 
kinetics.  Historically, polymers have been strong contenders in the field.  However, 
achieving a narrow polydispersity and reducing batch-to-batch variability in synthesis 
can be difficult.  Therefore researchers have expanded to other materials such as 
lipids, which mat have more favorable drug release properties.  Lipids are a 
chemically unique category of molecules that plays a role in functionality and 
architecture of all living cells.  Thus when used as materials for design of drug 
delivery systems, they will be considered biodegradable and biocompatible.  In 
addition they offer more robust control over design of molecular architecture and thus 
directly impact the release kinetics of model drugs. 
The aim of this study was to better understand the mass transport mechanism 
involved in controlled release of a model drug from lipid based parenteral delivery 
systems.  A family of dihydroxyacetone (DHA) derived symmetrical lipids with 
varying hydrocarbon chain length was synthesized to systematically analyze how lipid 
chain length influences drug release kinetics.  Our results showed that microparticles 
prepared using solvent emulsification are porous and polydisperse in size.  The effects 
of several formulation and processing parameters (lipid and surfactant concentration) 
on the resulting release kinetics were measured.  As expected smaller particles 
(<25µm) showed faster release kinetics possibly due to shorter diffusion pathway 
length compared to the larger particles ([25-40] µm and >40 µm).  Our results showed 
  
that porosity controls the release kinetics of the anti-inflammatory drug piroxicam 
more strongly than hydrophobicity.  
Further investigation of parenteral delivery systems made from DHA derived 
symmetrical diglcycerides showed that protein release is dependent on the 
hydrophobicity of the matrix.  With lysozyme as a model protein drug, long chain 
diglycerides (C16 and C14) showed slower release compared to short chain, less 
hydrophobic diglycerides (C10  and C12).  As with solid microparticles, the effect of 
varying formulation and processing parameters (e.g. lysozomal loading, compression 
force) was studied. SDS gel electrophoresis and enzymatic study in M. lysodeikticus 
suspensions were used to study the structural integrity and activity of dispersed model 
drug.  The results showed that there is slight aggregation and loss of activity possibly 
as a result of heat generation during compression.  Furthermore diglyceride implants 
showed acute inflammatory response in early time points of the biocompatibility study 
conducted using rat animal models.  The inflammatory response subsided for later 
time points.  Histological inspection of the tissues showed presence of granulomas but 
no sign of tissue necrosis. 
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CHAPTER 1 
 
SYNTHETIC AND BIOLOGICAL MATERIALS FOR DRUG DELIVERY 
1. Introduction 
In the past few decades medicine and pharmacy have faced many new 
challenges.  These challenges, which range from the need for better and more effective 
cancer treatments1, 2 to treatment of widespread and chronic disease that are caused by 
a combination of hereditary and environmental triggers (e.g. diabetes mellitus), have 
led to breakthrough innovations in the field of drug delivery.  However, despite the 
role of fast-paced genomic and proteomic research in discovering the molecular basis 
for many diseases, and the use of tools such as combinatorial chemistry combined 
with computer-assisted rational design for high throughput synthesis of new 
biomaterials, the progress toward better therapies has been slow. Translation of 
innovative therapeutics from bench-top to bedside is often held back by lack of 
investment in developing new drug delivery technologies that can improve the 
efficacy of treatments 3, 4.  
1.1. Drug delivery and importance of controlled release 
The two most important aspects of controlled release drug delivery are spatial 
placement and temporal delivery of the therapeutic compound.  Spatial placement 
refers to the targeting necessary to achieve a therapeutic dose of a particular drug 
within a specific tissue, while minimizing exposure of healthy tissue to the drug. 
Temporal delivery refers to controlling the timing of drug delivery to the targeted site.  
These two factors are important to incorporate in an optimal design for novel drug 
delivery systems3. An example of where temporal delivery can help includes the 
  2 
delivery of protein and peptides. Their short in-vivo half lives and their sensitivity to 
physiological pH marks a challenge in their delivery5.  Examples of where spatial 
delivery can help include cancer therapy drugs.  The role novel delivery systems play 
in decreasing toxicity by their encapsulating matrices allow their local implantation at 
the tumor site and thus improving safety and efficacy of chemotherapy treatments 6, 7.  
Drug release rates have direct implications on the therapeutic effect of drug 
delivery systems (DDS).  Failure to release the drug in a timely manner could result in 
drug levels below the therapeutic window; while rapid release of the drug from the 
carrier could lead to drug levels exceeding the maximum tolerated dose or even enter 
the toxic range3. Table 1.1 gives examples of problems exhibited by free drugs that 
can be addressed through use of DDS. In controlled drug delivery, drug release from 
the carrier generally occurs by one of three mechanisms (or a combination thereof): (i) 
diffusion, (ii) chemical reaction, and (iii) solvent activation and transport. In the case 
of (i) diffusion-controlled system, two main geometries exist, either a reservoir that 
encapsulates the drug within a barrier, or a matrix in which the drug is uniformly 
distributed.  In either case, diffusion through the matrix is the rate-limiting step.  For 
delivery systems that (ii), release the drug as a result of a chemical reaction, the drug 
is released due to chemical degradation of the matrix.  Alternatively, the drug can be 
attached to a polymer/lipid by a covalent bond that can be either hydrolyzed or 
enzymatically cleaved, thus resulting in drug release.  A third mechanism is (iii) 
solvent activation. In such systems, the matrix containing the drug swells because of 
osmotic effects and external water entering the drug delivery systems pushes the drug 
out 8-13.  A number of materials have been used in the design of controlled delivery 
systems, including both lipids and polymers.  The following is a brief review of 
particles, implants, and vesicles made from polymers and lipids and their advantages 
and shortcomings. 
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Table 1.1. Non-ideal properties of drugs and their therapeutic implication (modified 
from 3) 
 
Problem Implications Effect of DDS 
Poor solubility 
Human body is composed of 
70% water, thus administrating 
hydrophobic drugs can result in 
precipitation in aqueous media. 
Use of excipients such 
Cremphor to solubilize highly 
hydrophobic drugs results in 
unacceptable side effects. 
Using hydrophobic 
carriers, such as lipid 
micelles or liposomes 
provides both hydrophobic 
and hydrophilic 
environments, resulting in 
enhanced drug solubility. 
Tissue damage on 
extravasation 
Accidental burst release will 
expose the tissues to toxic 
concentrations of the drug, 
resulting in necrosis. 
Regulated drug release 
from DDS, can reduces or 
eliminate tissue necrosis. 
Quick breakdown of 
the drug in vivo 
Loss of therapeutic activity upon 
administration, due to acidic pH, 
enzymatic processes 
DDS protects the drug 
from premature 
degradation while 
functioning as a sustained 
release system. In addition, 
lower doses of the drug 
may be required. 
Undesirable 
pharmacokinetic 
Rapid clearance of the drug 
upon administration, thus 
requiring high doses or 
continuous infusion. 
DDS can significantly alter 
the PK of the drug and 
reduce clearance rate. 
Poor biodistribution 
and absence of 
selectivity for target 
tissue 
Unnecessary exposure of 
healthy tissue to drugs because 
of widespread biodistribution 
can result in dose-limiting side 
effects. 
DDS can lower the volume 
of distribution and help to 
reduce side effects. In 
return it can also increase 
drug concentration through 
the EPR effect. 
1.2. Parenteral therapies 
Drug delivery systems aim to enhance the pharmacological properties of 
conventional (“free”) drugs.  Parenteral therapies denote a category of DDS that are 
designed to bypass the body’s natural defense against microbial invasion associated 
with skin and mucosal tissues14.  Parenteral, from para entron, meaning to “avoid 
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intestines”, refers to all administration principles for drugs that do not utilize the 
alimentary canal for the delivery of a drug to tissues.  The advantages of parenteral 
delivery include predictable pharmacokinetic as well as the ability to interdict a 
rapidly progressing lethal process or disease (e.g., injection of adrenalin to prevent 
cardiac arrest) 14.  In addition parenteral delivery systems are designed to reduce the 
administration frequency, and to protect the drug against degradation upon 
administration, while accurately controlling the release rate.  Examples of such 
systems include particulate carriers, implants, and emulsions15.  
1.2.1. Lipids 
 Lipids are one chemically unique category of drug delivery materials that play 
a fundamental role in the architecture and functionality of all living cells.  The wealth 
of information that exists on lipid ingestion, solubilization, and subsequent processing, 
provides the basis for semi-empirical design of lipid-based delivery systems.  Such 
systems cover a wide range of modalities such as liposomes, solid lipid particles 
(nano/micro), implants, emulsions, and nanostructured lipid carriers. 
1.2.1.1. Liposomes 
Liposomes, in the broadest sense, are colloidal particles composed of a 
phospholipid bilayer enclosing an aqueous core.  The bilayer structure allows 
incorporation of hydrophilic drugs into the aqueous core and incorporation of 
hydrophobic drugs into the lipid bilayer.  These formulations have played a significant 
role in improving delivery of potent drugs since their discovery in the 1960s.  Today, 
the majority of drug delivery systems approved for parenteral administration are 
liposomal formulations, Table 1.2.  Most of these formulations approved for use in 
humans contain phosphotidylcholine (neutral charge), with fatty acyl chains of varying 
lengths and degrees of saturation16.  Important challenges associated with liposomal 
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formulation are limited physical stability of the dispersions, burst release, low activity 
due to non-specific tumor targeting, non-specific clearance by reticuloendothelial 
system (RES), and difficulties in production scale up17.  Some of these limitations still 
remain as obstacles in developing new formulations. 
The liposomal fate in vivo is greatly impacted by their size, charge, pH, and 
their lipid constituents.  These properties can be adjusted to overcome some of the 
aforementioned limitations in liposomal delivery systems.  For examples, leakage of 
small molecular weight drugs in presence of blood plasma prompted the insertion of 
cholesterol and high melting point lipids such as hydrogenated lecithin, distearyl 
phosphotidylcholine (DSPC) and sphingomyelin (SM) into the bilayer, thus resulting 
in a less permeable barrier 16, 18, 19. 
Table 1.2. Examples of liposomal formulations 
Agent Administration Formulation Refs. Application 
Paclitaxel Systemic Liposome 20, 21 Antineoplastic agent 
Monophosphoryl 
lipid A and QS21 Systemic Liposomes 
22 
Vaccine adjuvant 
systems against 
hepatitis B 
Cytarabine Systemic Liposomes 23, 24 
Leukemic and 
lymphomatous 
meningitis 
Doxorubicin Systemic PEGylated liposomes 
25, 26 
Metastatic breast 
cancer, mullerian 
carcinoma, cervical 
cancer, advanced soft 
tissue sarcomas 
Daunorubicin Systemic Liposomes 27 Myelogenous leukemia 
Recombinant 
factor VIII Systemic Liposomes 
28 Hemophilia A 
Human interferon 
beta Systemic 
Cationic 
liposomes 
29 Gene therapy for advanced melanoma 
 
Rapid clearance of liposomes by the RES has been addressed by insertion of more 
hydrophilic groups such as polyethylene glycol (PEG).  The hydrophilic shield 
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provided by the PEG groups increases the circulation time of liposomes in the system 
by reducing the rate of plasma protein adsorption on the hydrophilic surface.  The 
therapeutic potential of liposomal formulation was expanded when a detailed 
understanding of lipid polymorphisms, physiological mechanisms of in vivo liposome 
deposition, and lipid-drug and lipid-protein interaction emerged.  These data resulted 
in enhanced design of liposomal systems with increased in vivo stability and improved 
biodistribution16.  
1.3. Particles 
Particulate drug delivery systems are the principle drug carrier in experimental 
pharmaceutics and clinical medicine.  The critical factor affecting in vivo particle 
distribution is size; particles with diameters larger than 1 µm are best described as 
microparticles and those smaller than 1 µm are referred to as nanoparticles.  The size 
distinction causes major differences at various levels, from formulation to in vivo 
usage 30. 
1.3.1. Lipid particles 
Solid lipid particles are made from solid lipids (i.e. lipids that are solid at room 
and body temperature) and are stabilized by surfactants.  By definition, the lipids can 
be purified triglycerides, complex glyceride mixtures (mono-, di-), and waxes31-33. 
Key advantages of solid lipid particles include their excellent physical stability, their 
ability to protect encapsulated labile drugs from degradation, and their amenability to 
function as controlled release systems 17. 
1.3.2. Solid lipid nanoparticles 
Solid lipid nanoparticles (SLN) are usually made by means of high-pressure 
homogenization and are mainly characterized by their less than 500 nm size. A clear 
advantage of SLN is the use of physiological lipids, which lower the risk of acute and 
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chronic toxic responses.  Furthermore, the absence of organic solvents in the 
production of SLN makes these delivery systems suitable candidates for parenteral 
delivery. Characterization of SLN has shown that methods of preparation, lipid 
composition, and choice of emulsifier, have a direct impact on the final size, charge, 
and stability of these particles.  In addition, the degree of lipid crystallinity and the 
modification of lipids are strongly correlated with drug incorporation, and the release 
rates from SLN 33.  However, the rapid clearance of nanoparticles from the body by 
liver and spleen has limited the usefulness of SLN.  While this response is 
advantageous for those particular cases where the spleen and liver are the targeted 
delivery sites, for delivery to other major organs and to prolong the circulation time, 
polymers such as block polyoxyethylene polypropylene copolymer are used to create a 
hydrophilic coating on the SLN34. 
1.3.3. Solid lipid microparticles 
Similar to SLN, solid lipid microparticles (SLM) are prepared from lipids that 
are solid at body and room temperature. The methods of preparation range from 
solvent evaporation, to oil in water (O/W) and water in oil (W/O) melt dispersion, 
multiple emulsion techniques, and high-pressure homogenization.  The chemical and 
physical characteristics of the drug candidate dictate the preparation technique of 
SLM. Studies have shown that SLM show high encapsulation efficiencies for 
lipophilic drugs.  Jaspart et al. reported successful encapsulation of salbutamol 
acetonide, a bronchodilator agent, for pulmonary delivery via SLM35, 36.  Reithmeir et 
al. reported successful encapsulation of thymocartin and insulin for parenteral release, 
and Saraf et al. demonstrated encapsulation and delivery of hepatitis B surface antigen 
for mucosal immunization37, 38. The shortcomings associated with SLM delivery 
include low encapsulation efficiency of hydrophilic drugs and lipid polymorphism 
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during storage.  However, studies have shown that SLM are non-toxic in vivo, thus 
more research is needed to fully exploit the therapeutic potential of SLM36, 39. 
1.4. Lipid implants 
The use of lipid implants as a parenteral controlled drug delivery system 
provides an interesting alternative for protein and peptide drugs.  The acidic 
microenvironment within traditional polymeric delivery systems, and the preparation 
steps of these matrices can compromise the stability and functionality of protein and 
peptide drugs, while preparation methods of lipid implants offer a less caustic 
approach to encapsulation of proteins and peptides 15, 40-46.  In addition to providing 
protection for drug molecules, and allowing accurate control of the release rate, lipid 
implants can be used to obtain locally restricted drug distribution.  Formation of 
biofilm on the surface of prosthetic implants often leads to persistent infection and 
inflammation, as well as local and systemic toxicity resulting in overall failure of the 
implant.  To decrease and prevent these side effects, a locally high concentration of 
antibiotic is needed, but because of inadequate vascularization at the wound site, 
conventional routes of delivery such as intravenous and intramuscular delivery fail to 
achieve a sufficient drug concentration.  The use of antibiotic loaded lipid implants 
has proven to be an effective delivery route. Implants not only offer local and 
proximal delivery at the wound site, but they can also decrease the unnecessary 
exposure of other organs to drug molecules47, 48. 
1.5. Polymeric systems 
Polymers offer a vast array of versatile designs for drug delivery applications, 
for example, through covalent conjugation directly to a drug molecule, or via use of 
electrostatic forces to form polyplexes, or by encapsulating the drug within the 
polymer.  Understanding the structure-function relationship between a polymer’s 
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molecular architecture and its inherent properties is an important aspect for their 
design in drug delivery applications.  Research has shown that molecular weight (Mw), 
polydispersity, charge, and the hydrophilic-hydrophobic character of polymer’s main 
chain directly affects the biodistribution, clearance rate, toxicity, and biological 
activity of polymeric drug delivery matrices.  
Polymers used as biomaterials can be naturally occurring, synthetic, or a 
combination of both.  The characteristics of the main groups of polymeric materials 
used for drug delivery are summarized in Tables 1.3 and 1.4.  Despite the abundance 
of naturally occurring polymers, their utilization has been limited by irreproducible 
production methods.  Their structural complexity renders modification and 
purification tasks challenging.  Additionally, significant batch-to-batch variations 
occur because of their “bio-preparation” in living organisms (plants, crustaceans). In 
contrast, synthetic polymers are available in a wide variety of molecular compositions 
with easily adjustable properties.  Processing, copolymerization, and blending provide 
simultaneous means of optimizing a polymer’s mechanical characteristics and its 
diffusive and biological properties.  Their primary obstacle is the general lack of 
biocompatibility of the majority of the synthetic materials, although poly(ethyelene 
oxide) (PEO) and poly(lactic-co-glycolic acid) (PLGA) are notable exceptions.  
Therefore, synthetic polymers are often associated with inflammatory reactions, 
limiting their use to solid, unmoving, and impermeable devices49. 
Poly(lactic acid) (PLA), poly(glycolic acid) (PGA) and their copolymer PLGA 
are one of the most well-studied family of biomaterials with regard to use in drug 
delivery applications50.  PLGA has been so extensively studied because of its 
biocompatibility and the ease of varying its properties by altering the copolymer 
composition, as well as its inclusion in a number of Food and Drug Administration 
(FDA) approved devices. Examples of drugs studied for delivery via encapsulation 
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within PLGA matrix include, piroxicam, neurotrophic growth factor (CNTF), 
leuprolide (LupronDepot) or triptorelin (Trelstar) 51-53.  However, despite successful 
encapsulation and delivery of the above drugs, polymeric drug delivery faces a 
challenge for delivery of protein therapeutics and peptides.  Presence of acidic 
microclimates within the PLGA particles causes denaturation and aggregation and 
ultimately leads to incomplete release of inactive proteins, therefore, more research is 
needed to optimize the design and delivery of proteins and peptides using polymeric 
matrices 40, 54. 
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Table 1.3. Summary of the main properties and applications of the naturally occurring 
polymeric biomaterials (adapted from 49) 
 
Polymer Main application Biodegradable 
Protein and protein-based 
polymers 
 
Collagen 
 
 
Albumin 
Absorbable, biocompatible, elastic properties 
allow use in implants and in tissue 
engineering. 
 
Drug delivery microspheres, sponge wound 
dressing, and absorbable sutures 
 
Used as a model drug in microsphere 
encapsulations 
 
 
 
Yes 
 
 
Yes 
 
Poly(amino acids) 
poly(α, L-amino 
acids) 
 
Generally non-antigenic and biocompatible. 
Used as oligomeric drug carriers. 
 
Yes 
 
Polysaccharides and 
derivatives 
 
Plant sourced 
Agarose 
 
Alginate 
 
 
 
Carboxymethyl 
cellulose 
 
 
 
Human/animal sourced 
 
Hylauronic acid 
 
Heparin and  
glycosaminoglycanes 
 
Microbial polysaccharides 
Dextrans and its 
derivatives 
Chitosan and its 
derivatives 
Immobilization matrices for cells and 
bioactive molecules 
 
Major use as supporting materials in clinical 
analysis and as an immobilization matrix. 
Use as immobilization matrices for cells and 
enzymes, controlled release of bioactive 
molecules, injectable microcapsules for 
treating neurodegenerative disease. 
 
Use in drug delivery systems and dialysis 
membranes. Utilizing a combination of 
ionotropic gelation and polyelectrolyte 
complex formation for cells immobilization. 
 
Important lubricant properties, potential 
therapeutic reagent. 
Antithrombotic and anticoagulant properties 
utilized in surgical procedures. A major 
candidate for ionotropic gelation and capsule 
formation. 
 
 
Widely used as a drug carrier with excellent 
rheological properties 
Positively charged and biocompatible with 
major applications in controlled delivery 
systems (i.e. gels, microspheres, membranes).  
Yes 
 
 
Yes 
 
 
 
 
 
 
No 
 
 
 
 
 
Yes 
 
Yes 
 
 
 
 
  
 Yes 
 
Yes 
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Table 1.4. Summary of the main properties and applications of synthetic polymeric 
biomaterials (adapted from 49) 
 
Polymer Main application Biodegradable 
Aliphatic polyesters 
Poly(lactic acid), 
poly(glycolic acid) and their 
copolymers 
 
 
Poly(hydroxy butyrate), 
poly(ε-caprolactone) and 
copolymers, poly(alkylene 
succinate), etc. 
 
Tunable degradation kinetics, used in drug 
delivery systems and tissue engineering 
applications.  
 
Utilized as a matrix for drug delivery 
system and cell microencapsulation. 
Properties can be changed through chemical 
modification and blending. 
 
Yes 
Polyamides (Nylons) Non-absorbent sutures, haemofilteration membranes. No 
Polyanhydrides Biodegradable, used in tissue engineering and release of bioactive molecules. Yes 
Poly(ortho esters) Surface eroding polymer, with applications in sustained delivery, ophthalmology. Yes 
Poly(cyano acrylates) 
Biodegradable, depending on the length of 
the alkyl chain. Used widely as surgical 
adhesive. 
Yes 
Polyphosphazenes 
Can be tailored for side chain functionality. 
Cast-able into films and hydrogels, with 
applications in drug release. 
Yes 
Thermoplastic polyurethanes 
Elastomeric properties that can be tailored 
through composition change of the starting 
materials. Used as (prostheses, vascular 
grafts), catheters, and drug delivery systems.  
No 
Polyethylene (low density) Surgical sutures, catheters, membranes. No 
Poly(vinyl alcohol) Gels and blends are used in drug delivery and cell immunoisolation. Yes 
Poly(ethylene oxide) 
Highly biocompatible. Derivatives and 
copolymers have been utilized in drug 
delivery applications. 
Yes 
Poly(hydroxyethyl 
methacrylate) 
Soft contact lenses, skin coating and 
immunoisolation membranes. No 
Poly(methyl methacrylate) Dental implants and bone replacements. No 
Poly(tetrafluroetheylene), 
Polydimethylsiloxanes Vascular grafts, clips, sutures, and coatings. No 
Environmentally responsive 
polymers 
Poly(ethylene oxide-b-
propylene oxide) 
Poly(vinyl methyl ether) 
 
Poly(N-alkylacrylamides) 
 
 
Surfactants with amphiphilic properties used 
in protein delivery and skin treatments. 
Non-toxic, temperature sensitive with 
excellent shape-memory properties. 
Temperature-sensitive gels with adjustable 
lower critical solution temperature via co-
monomer incorporation. 
 
 
Yes 
 
  13 
1.6. Drug-conjugated delivery systems 
Covalently conjugated delivery systems are designed to exploit the endocytosis 
pathway in cells.  Endocytosis is a mechanism by which cells take up macromolecular 
nutrients (e.g. cholesterol in the form of lipoprotein particles, iron complexes with 
transferrin) that are unable to enter the cell through passive diffusion.  Endocytosis is a 
general term describing three complex sub-pathways: (i) pinocytosis, by which a cell 
uptakes solutes and single molecules such as proteins; (ii) phagocytosis, by which cell 
ingests large objects such as viruses, apoptotic cell debris, and bacteria and (iii) 
receptor mediated endocytosis, by which a cell ingests compounds when triggered by 
specific ligand binding. Pinocytosis and phagocytosis are non-receptor mediated forms 
of endocytosis and may result in unspecific uptake of particles and/or proteins. In 
contrast, receptor mediated endocytosis is triggered by specific ligand binding.  The 
combination of receptor mediated endocytosis and phagocytosis/pinocytosis is the 
basis for design of targetable polymeric carriers 55, 56.  
A drug conjugated with a polymer is referred to as a “pro-drug”, which is an 
inactive precursor of a drug that protects and delivers the drug to a specific site.  Pro-
drugs have several advantages: (i) an increased solubility of hydrophobic drug, serving 
to increase the bioavailability, (ii) protection and preservation of the drug’s therapeutic 
activity during circulation, transport to a targeted organ and intracellular trafficking, 
(iii) reduced immunological response, (iv) improved drug targeting through 
functionalized moieties of the construct, and (v) the potential to form advanced drug 
delivery complexes.  An ideal pro-drug structure, generally referred to as the 
Ringsdrof model, will contain the following components: an inert polymeric 
backbone, a functionally active spacer, a target moiety, and a drug molecule 57, 58. 
Various molecular architectures of polymers have been studied for the design 
of drug conjugates, however two polymers have been most commonly examined, 
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poly(ethylene glycol) (PEG) and N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymer. Kopeček and colleagues developed N-(2-hydroxypropyl)metacrylamide 
(HPMA).  It consists of a hydrophilic polymer that significantly increases water 
solubility of hydrophobic drugs, and has proven to be biocompatible.  Insulin and 
ampicilin are examples of drugs that have been attached to HPMA through aminolysis 
of reactive polymeric precursors.  Doxorubicin, an anthracyline antibiotic with a broad 
spectrum of antitumor activity, has been attached via a polypeptide spacer56, 59, 60.  
Other examples of HPMA-based prodrugs include chemotherapeutic agents such as 
cis-diamminedichloroplatinum(II) (cis-platin), which is widely used in treatment of 
solid tumors including ovarian, testicular, and head and neck cancers. 
Frank Davis and colleagues developed the first generation of PEGylated 
proteins and peptides in the late 1970s.  Their findings showed that the PEGylated 
complex was 5 to 10 times larger than the free drug form due to the binding of water 
molecules to the ethylene glycol subunits, which decreases renal clearance rates, and 
improves the pharmacodynamic and pharmacokinetic properties of PEGylated 
polypeptide drugs 61.  Weekly injections of IFN-α2 conjugated to a 40 kDa branched 
PEG for the treatment of chronic hepatitis C have resulted in near constant blood 
concentrations of IFN-α2, and a 100-fold decrease in renal clearance 62, 63. 
1.7. Goals of this study: 
The objective of this study was to investigate dihydroxyacetone-derived (DHA) 
diglycerides and their analogs as new materials for the preparation of parenteral 
controlled release matrices.  The main goals were to characterize the biomaterial to 
facilitate the design and preparation of controlled release matrices, and to ensure the in 
vivo safety of these matrices.  Herein we report the synthesis of a series of bioinspired 
symmetrical lipids comprised of two classes of biomolecules: fatty acids and DHA. 
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DHA is a constituent of the glycolysis pathway, and is FDA approved for oral and 
topical administration, making it an attractive building block for new biomaterials 64-
66.  The particular advantage of using DHA as a lipid building block for this study is 
that the strong dipole moment of the DHA carbonyl maintains the lipids in the solid 
state while the lipid lengths are varied.  Symmetrical glycerol analogues of the lipids 
reported herein are liquids and waxes, rather than solids.  This study describes the 
synthesis and characterization of nine symmetrical lipids, with incrementally 
increasing aliphatic lipid tails, their fabrication into solid lipid microparticles, and the 
investigation of how the lipids influence particle morphology, and the controlled 
release kinetics of the model drug compound (Chapter 2).   
We show that that the release kinetics of a hydrophobic drug model increased 
with increasing lipid length.  SEM images, as well as particle density calculations 
collectively suggested that the microparticle porosity was the primary factor that 
controlled release kinetics, as microparticle porosity increased with increasing lipid 
length.   
Chapter 3 focuses on the synthesis and characterization of the symmetrical 
analogues of these lipids, and their potential for delivery of proteins and peptides as 
model drugs.  Our results demonstrate that wettability effects often play a crucial role 
in release of high molecular weight model compounds from lipidic matrices.  Thus, 
release behavior of proteins can be tailored by varying the lipophilicity of the matrix 
material via selectively varying the fatty acid chain length.  The symmetrical 
diglycerides showed excellent properties for retaining physical and chemical 
characteristics of these model pharmaceuticals.  However, the burst effect in release 
behavior limits their use for prolonged drug release applications.  The burst release, 
possibly due to less than desirable mechanical properties of diglyceride powders may 
be remedied through forming blends with other lipids such as cholesterol.  
  16 
Biocompatibility studies of diglycerides implants in rats showed acute inflammatory 
response after the 2-day time point.  However, implants for later time points showed 
no sign of tissue necrosis or damage (7,14 and 28 days).   The final remarks (Chapter 
4) focus on future experiments that can bring about a better understanding of 
mechanical behavior of diglycerides powders and its effects on the release of the 
macromolecules. 
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CHAPTER 2 
 
SOLID LIPID MICROPARTICLES FOR CONTROLLED DRUG DELIVERY  
2. Introduction 
Microparticulates serve in the pharmaceutical field as injectable systems to 
control the spatial and temporal release of drugs1-7.  A range of materials have been 
used for the microparticle matrix such as synthetic and natural polymers (i.e. 
poly(lactic-co-glycolic acid), collagen, gelatin and chitosan).  More recently, lipids 
(i.e., cholesterol, phospholipids, lecithin, fatty acids, waxes and glycerides with fatty 
acids of variable chain length) have emerged as a new class of material that may be 
suitable for microparticle-based controlled drug delivery8-18.  Lipid materials have a 
high variability of available structures permitting the design of predetermined drug 
release profiles.  In addition, the use of physiological components in the design of 
lipid systems merges their multifunctional character with their potential to create a 
biocompatible material.  Several studies support the potential use of solid lipids for the 
delivery of both hydrophobic and hydrophilic molecules, as well as the controlled 
release of peptides and proteins.  Although the solid lipid matrix literature is fairly 
extensive, there has yet to be a systematic investigation of how the lipid matrix can be 
engineered at the molecular level to modulate the functional characteristics of the 
microparticle.  Specifically, there is little understanding of how lipid structure, 
particularly lipid length, influences microparticle fabrication, microparticle 
morphology, and drug release kinetics. 
Herein we report the synthesis of a series of bioinspired symmetrical lipids 
comprised of two classes of biomolecules, fatty acids and dihydroxyacetone (DHA).  
DHA is a constituent of the glycolysis pathway, and is FDA approved for oral and 
topical administration, making it an attractive building block for new biomaterials28-31.  
  24 
The particular advantage of using DHA as a lipid building block for this study is that 
the strong dipole moment of the DHA carbonyl maintains the lipids in the solid state 
while the lipids’ lengths are varied.  In fact, symmetrical glycerol analogues of the 
lipids reported herein are liquids and waxes, rather than solids.  This study describes 
the synthesis and characterization of five symmetrical lipids with incrementally 
increasing aliphatic lipid tails, their fabrication into solid lipid microparticles, and the 
investigation of how the lipids influence microparticle fabrication, morphology and 
controlled release kinetics of a model drug compound.   
2.1. Materials and Methods 
Hexadecanoyl chloride, tetradecanoyl chloride, dodecanoyl chloride, decanoyl 
chloride, ocatanoyl chloride, 1,3-dihydroxyacetone dimer 97% (DHA), chloroform, 
anhydrous pyridine and piroxicam were all obtained from Sigma-Aldrich (Saint Louis, 
MO) and used without further purification.  Poly(vinyl alcohol) (PVA, MW∼25,000, 
88 mole% hydrolyzed) was purchased from Polysciences Inc. Dichloromethane 
(DCM), acetone, tetrahydrofuran (THF) and diethyl ether were purchased from 
J.T.Baker (West Chester, PA).  All reagents and solvents were used as received 
without additional purification  
2.1.1. Lipid synthesis and characterization 
Symmetrical lipids were synthesized through modification of a previously 
reported method by Bentley and McCrae32.  The general procedure is as follows, using 
the synthesis of C16 symmetrical lipid as an example: DHA (3.5 g, 39 mmole) was 
stirred in anhydrous chloroform (150 mL) under flow of N2 at room temperature, 
followed by sequential dropwise (1 drop/sec) addition of hexadecanoyl chloride (22.1 
mL, 80 mmol) and anhydrous pyridine (7.5 mL), in that order (Figure (2.1A)). The 
mixture was stirred at 800 rpm for 3 hrs at room temperature, and the color varied 
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from clear to slightly yellow.  The reaction was extracted with deionized water (2 × 75 
mL), the combined aqueous layers were washed with chloroform (1 × 75 mL). All 
chloroform layers were combined before removal by rotoevaporation in vacuo to a 
thick white/yellow residue. The residue was dissolved in dichloromethane:ether (1:1), 
in the lowest volume needed, and placed in the freezer to crystallize overnight 
(yield~70%).  Uncorrected melting points were collected on a Fisher-Johns melting 
point apparatus.  1H-NMR spectra were recorded at room temperature with a Brucker 
AF-300 spectrometer operating at 300.13 MHz, and elemental analyses were obtained 
through QTI (Whitehouse, NJ).  
2.1.2. Fabrication of solid lipid microparticles (SLM) by spontaneous 
emulsification  
Each lipid (0.1 g) was dissolved in a 3:2 (v:v) ratio of DCM:acetone by 
vigorous vortex for approximately 10 seconds.  The lipid solution was transferred 
using a glass pipet into a stirring PVA solution as a slow and steady stream (450 mL, 
2.5%). The suspension was stirred for 3 hrs to allow evaporation of the organic 
solvents and hardening of the microparticles.  Microparticles were isolated by 
centrifugation at 4,800 RCF for 60 minutes followed by multiple washes (3×) with 
deionized water and centrifugation at 4,800 RCF for 45 minutes.  The particles were 
resuspended in deionized water (5 mL), and lyophilized for a minimum of 12 hrs and 
were stored at -20 °C in the presence of desiccant.  The final products were fine 
powders with approximate yields of 75% (relative to original weight of lipid).   
Particles containing the model drug (piroxicam) were prepared using the same method 
with the exception that the model drug and lipid were co-dissolved at 5:100 weight to 
weight ratios, in DCM:acetone before addition to the surfactant solution as noted 
above. 
  26 
2.1.3. Particle characterization 
The solid lipid microparticles were analyzed by two different methods to 
determine their geometric and aerodynamic size distributions.  All measurements 
assume spherical geometry.  The size distributions of each sample were collected until 
there were no changes in the overall shape of the distribution curve.  For each method, 
the total number of counted particles was >100,000. 
Geometric sizes of lipid particles in powder form were determined in isotonic 
diluent (Isoton II) by a Coulter Multisizer III (Beckman Coulter Inc.) equipped with a 
100 µm aperture.  About 5 mg of a given powder sample was added to 20 mL of 
Isoton II and each suspension was shaken for one minute to deagglomerate the 
particles.  Any bubbles were allowed to dissipate prior to measurement.  
Particle morphology was studied at low voltage (5 kV) using scanning electron 
microscopy imaging (LEICA 440) after coating with palladium.  Surface charge on 
samples suspended in 1:10 diluted PBS was measured using a Malvern Zetasizer-Nano 
ZS (Malvern, UK).  
2.1.4. Contact angle measurements 
A PRECO Hydraulic press (Los Angles, CA) was used to make lipid pellets 
with approximate surface area of 25 mm2.  For contact angle measurements, a ramé-
hart contact angle goniometer (100-FO) was used to measure the sessile contact angle 
of water on a lipid pellet surface.  Unless otherwise stated, measurements were 
conducted in triplicate.  
2.1.5. In vitro drug release 
The encapsulation efficiency of lipid microparticles was determined via 
complete drug recovery from dissolved microparticles, followed by comparison with 
the theoretical maximum drug loading.  Microspheres (1 mg) were dissolved in THF 
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(1 mL) and the piroxicam concentration was measured by UV absorbance at λ=276 
nm using a microplate spectrofluorometer (Spectramax GeminiEM; Molecular 
Devices, Sunnyvale, CA).  In vitro release kinetics were determined by suspending 5.0 
mg of microspheres in 1 mL of PBS with 0.05% Tween-20 in microcentrifuge tubes 
(Eppendorf) and incubating at 37 °C under gentle rotation.  The supernatant was 
collected in total for UV measurement at predetermined time intervals to determine 
the amount of release, and replenished with fresh buffer.  Piroxicam concentration was 
measured at λ=276 nm and quantified according to a standard curve of piroxicam 
prepared by dissolving the drug in PBS with 0.05% Tween-20. 
2.1.6. Kinetic analysis of the release data 
The release mechanism of piroxicam from solid lipid microparticles was 
investigated using data corresponding to the 2-300 hours of drug released according to 
the following mathematical models, Tables 2.3-2.5. 
Ritger-Peppas model: This model is often applied to describe drug release from 
matrices of various geometries using a simple power law relationship 33: 
 
(1) 
 
where       represents the fractions of released drug at time t, with k the release rate 
constant characteristic of the controlled-release device and n, the diffusional exponent, 
which also indicates the mechanism of the drug release. For spherical geometries, if n 
≤ 0.43, a Fickian diffusion, 0.43 ≤ n ≤ 0.85, a non-Fickian transport mechanism, and n 
≥ 0.85, a zeroth-order drug release mechanism. 
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Jander equation model: This particular model considers the change in the interfacial 
area where the drug release from microspheres occurs through diffusion within the 
matrix34. 
      (2) 
 
where k1 and kJ denote rate constants and r, is the radius of the spherical matrix. 
2.1.7. Lipid hydrolysis product analysis 
Dihydroxyacetone, sodium butyrate and lipid C4 were each separately suspended in 
hydrochloric acid (5 mL, 0.02 N, pH=1.67), and stirred at 37o C for two days, after 
which the pH was adjusted to neutral by addition of NaOH (1 N) and the solutions 
lyophilized for 48 hrs. The resulting powder was dissolved in deuterium oxide for 
analysis by 1H-NMR spectroscopy.  
2.2. Results and Discussion 
The symmetrical lipids were successfully synthesized via Schotten-Baumann 
acylation (following the method of Bentley and McCrae) with yields in excess of 70% 
(Figure 2.1(A)).  The acyl chlorides were chosen so that the final product was derived 
from physiological lipids; for example hexadecanoyl chloride, derived from 
hexadecanoic acid, was selected to synthesize lipid C16.  Each symmetrical lipid is 
abbreviated Cx where “x” denotes the number of carbons in the corresponding fatty 
acid. 
In addition, all of the synthesized lipids have melting points that are above 
room and body temperature, making them good candidates for fabrication into solid 
microparticles for controlled drug delivery.  Elemental analysis obtained for C8-C16 
lipids is summarized in Table 1. 1H-NMR (300 MHz, CDCl3, δ): [C8 lipid] 0.89 (t,6H), 
1.27 (s,16H), 2.43 (t,4H), 4.76 (s,4H), [C10 lipid] 0.89 (t,6H), 1.27 (s,24H), 2.43 
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(t,4H), 4.76 (s,4H), [C12 lipid] 0.89 (t,6H), 1.27 (s,32H), 2.43 (t,4H), 4.76 (s,4H), [C14 
lipid] 0.89 (t,6H), 1.27 (s,40H), 2.43 (t,4H), 4.76 (s,4H), [C16 lipid] 0.89 (t,6H), 1.27 
(s,48H), 2.43 (t,4H), 4.76 (s,4H), (Figure 1(B)).  
 
 
 
Figure 2.1. (A) Reaction pathway for the synthesis of symmetrical 1,3-lipids, (B) 1H-
NMR spectra of C12 lipid (dodecanoic acid 3-dodecanoyloxy-2-oxo-propyl ester). 
C12’s spectrum serves as a representative of the remaining lipids. 
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Table 2.1. Melting point and elemental analysis of solid lipids 
Elemental analysis 
(Theoretical) 
Elemental analysis 
(Experimental) Lipid sample Melting point  (oC) %C %H %C %H 
C16 76-78 74.13 11.75 74.05 11.41 
C14 73-76 72.87 11.46 73.18 11.54 
C12 69-70 71.32 11.08 71.32 11.14 
C10 64-65 69.31 10.62 69.30 10.81 
C8 56-58 66.63 10.01 66.57 10.23 
The sessile contact angle of water on each lipid surface was measured to establish the 
relative hydrophobicity differences among the lipids.  The hydrophobic nature of each 
lipid is important for two reasons.  First, lipids with insufficient hydrophobicity would 
be difficult to formulate into solid microparticles.  Second, significant variability of 
the lipid hydrophobicity could be used to control the rate of drug release from the 
microparticles in the same way hydrophobicity is used to regulate hydrolytic drug 
release from polymer-based microparticles35-36.  Generally, contact angles increased 
with increasing lipid length (Figure 2.2).  The contact angles show an increasing trend 
in hydrophobicity among the lipids, with the series straddling 90°, the angle at which 
surfaces transition from “hydrophilic” for short chain lengths to “hydrophobic” for 
longer chain length lipids. 
Microparticles containing piroxicam as a model drug were successfully 
fabricated from all lipids in the series using spontaneous emulsification.  
Encapsulation efficiencies for piroxicam were approximately 5-8% (w/w).  The level 
of encapsulation efficiency is a result of hydrophilic drug partitioning into the outer 
aqueous phase from the inner oil phase during emulsification.  The effect of lipid 
concentration and surfactant concentration (poly vinyl alcohol (PVA)) on the 
hydrodynamic particle size, with constant stirring rate and temperature, was 
determined by serial variation of both parameters.  The results showed that increasing 
the lipid concentration led to an increasing trend in mean diameter, and increasing the 
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surfactant concentration led to a decreasing trend in the mean diameter (Table 2.2).  
Zeta potential measurements showed that lipid microparticles are negatively charged. 
The negative surface charge can be attributed to the presence of hydrolyzed ester 
groups at the particle surface or presence of residual PVA on the particles (Figure 
2.3)8.  
 
 
Figure 2.2. Sessile contact angle of water           Figure 2.3. Zeta potential of lipid  
on each lipid surface.                           microparticles  
 
Table 2.2. Average mean diameter of lipid microparticles 
Lipid sample 
Lipid soln. 
(0.01 g/mL) 
2.5% PVA 
Lipid soln. 
(0.02 g/mL) 
2.5% PVA 
Lipid soln. 
(0.01 g/mL) 
5% PVA 
Lipid soln. 
(0.02 g/mL) 
5% PVA 
C8 39.6 ± 13 41.2 ± 12.3 28.8 ±11.3 37.8 ± 14.7 
C10 32.3 ± 13 35.6 ± 12.6 22 ± 9.36 33.6 ± 15.8 
C12 29.7 ± 13.5 36.6 ± 13.8 27.3 ± 12.1 28.4 ± 12.3 
C14 26.2 ± 14.1 29.7 ± 14 29 ± 12.3 17.6 ± 7.6 
C16 25.3 ± 11 24 ± 12.3 21.7 ± 9.75 26.1 ± 11.9 
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Figure 2.4. Lipid microparticle morphology as a function of lipid chain length. 
Clockwise from top-left, (A) C8 particle morphology showing a tightly packed 
morphology followed by (B) C10,, (C) C12, (D) C14, and (E) C16. Note the increasing 
porosity trend with increasing lipid chain length, the scale bar in each picture is 10 
µm. 
Inspection of the particles by SEM showed porous structures on the surface 
and throughout the matrix (Figure 2.4).  Particle porosity was a function of the lipid 
length, with the shorter lipids leading to denser particles.  Particles from the C8 lipid 
have a relatively smooth surface compared to C10 through C16 lipids.  Additionally, the 
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surface structures became more prominent as the lipid chain length increased.  The 
shape and structures of the pores formed are part of the inherent properties of the 
microparticle formulation method.  During spontaneous emulsification, the lipid 
concentration in the organic phase constantly increases until reaching a solubility limit 
after which the lipid starts to precipitate.  The rate at which the lipid precipitation 
takes place is a function of its solubility in the organic phase37.  As evident by the 
SEM pictures, short and medium chain length lipid (C8-C10 and C12-C14) result in coral 
shaped surfaces whereas longer chain lipid (C16) results in sheet like surfaces. 
Piroxicam, a non-steroidal anti-inflammatory molecule was chosen as a model 
drug because of its generalizable “drug-like” nature, thus presenting what is regarded 
as an accurate model for currently available therapeutic38-39.  The in vitro release 
behavior of piroxicam-loaded lipid microparticles was observed over a 300 hr period 
at 37 °C.  Because particle size can influence release kinetics, particles were sieved 
into three groups (>40 mm, 25-40 mm and <25 mm).  As expected, based on the 
literature, larger particle sizes showed slower release rates in comparison to smaller 
particles, possibly due to an increased diffusion pathway length, or smaller surface to 
volume ratio38,40-41.  The microparticles exhibited chain length-dependent release 
behavior, but in an unexpected manner with microparticles fabricated from longer 
chain lipid particles displaying faster release kinetics (Figure 2.5(A-C)).  Based on the 
hydrophobic character of these lipids, we anticipated that the rate of lipid hydrolysis, 
and therefore drug release rate, would be inversely proportional to lipid chain length; 
however, based on the SEM images and particle density calculations, it appeared that 
this release behavior was governed more strongly by microparticle porosity, and 
subsequently the surface area, than by lipid hydrophobicity.  
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Figure 2.5(A). Cumulative release of piroxicam-loaded lipid microparticles sized 40 
microns or larger.  
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Figure 2.5(B). Cumulative release of particles sized between 25 to 40 microns, (C) 
cumulative release of particles smaller than 25 micron, showing faster release 
compared to the larger particles. 
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Table 2.3. Kinetic assessment of dissolution data for release of piroxicam (pH 7.4), for 
particles d≤25µm 
Kinetic model Regression parameters a C8 C10 C12 C14 C16 
r2 0.8863 0.95331 0.8514 0.7054 0.7708 
n 0.3903 0.3 0.3253 0.3903 0.1761 Ritger-Peppas 
k 0.8069 1.6132 1.1253 4.0218 12.945 
r2 0.7914 0.8895 0.7343 0.596 0.6136 
kJ×10-2(h-1/2) 1.15 1.06 0.95 1.19 0.96 Jander’s equation 
Intercept 0.2336 0.2796 0.2581 0.3966 0.5488 
a Regression parameters (r2: determination coefficients, n: diffusional release 
exponent, kJ: Jander’s release rate constant) 
 
Table 2.4. Kinetic assessment of dissolution data for release of piroxicam (pH 7.4), for 
particles d~[25-40]µm 
Kinetic model Regression parameters a C8 C10 C12 C14 C16 
r2 0.821 0.9564 0.9215 0.9144 0.731 
n 0.3424 0.2941 0.2393 0.2708 0.1508 Ritger-Peppas 
k 0.3652 0.4698 0.6789 1.3628 8.8729 
r2 0.8265 0.9528 0.9052 0.8856 0.6221 
kJ×10-2(h-1/2) 0.04 0.04 0.04 0.09 0.2 Jander’s equation 
Intercept 0.0019 0.0018 0.0028 0.0057 0.0391 
a Regression parameters (r2: determination coefficients, n: diffusional release 
exponent, kJ: Jander’s release rate constant) 
 
Table 2.5. Kinetic assessment of dissolution data for release of piroxicam (pH 7.4), for 
particles d≥40 µm 
Kinetic model Regression parameters a C8 C10 C12 C14 C16 
r2 0.983 0.9604 0.9807 0.9891 0.7949 
n 0.2996 0.354 0.2594 0.2809 0.194 Ritger-Peppas 
k 0.5981 0.3036 0.5527 0.6983 5.0808 
r2 0.9431 0.926 0.9524 0.9239 0.9161 
kJ×10-2(h-1/2) 0.79 0.78 0.64 0.75 0.5 
Jander’s 
equation 
Intercept 0.1989 0.1613 0.191 0.2092 0.4422 
a Regression parameters (r2: determination coefficients, n: diffusional release 
exponent, kJ: Jander’s release rate constant) 
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To achieve a better understanding of the underlying release mechanism, the 
results were evaluated using two models, Ritger-Peppas, and Jander33-34.  The 
regression parameters for each model are listed in Table 2.3-2.5.  The determination 
coefficients of Ritger-Peppas model represent a better fit for the kinetic analysis, thus 
we choose to limit our discussion to this model.  The diffusional exponent for each 
release curve, for lipid particles across the length scale confirms the presence of 
Fickian diffusion mechanism of piroxicam (n≤0.43).  In addition, the calculated rate 
constants verify the increasing trend with decreasing particle diameter. 
Lastly, the lipids were designed to hydrolytically degrade to form DHA and 
free fatty acids, both of which are readily metabolized in the human body.  To 
establish that the degradation products of the lipids are DHA and free fatty acid, C8 
lipid was allowed to hydrolyze in acidified distilled water.  Dihydroxyacetone and 
sodium octoate were treated likewise and used as controls.  Unfortunately no common 
solvent could be identified to solubilize the degradation products for analysis by NMR 
because of the relatively hydrophilic nature of DHA and the relative hydrophobic 
nature of octanoic acid.  Because butyric acid and DHA are both water-soluble, we 
synthesized C4 lipid to determine its hydrolytic products as a proof of concept to 
determine the degradation products of symmetrical DHA lipids. 
Previous studies have shown that the dissolution of dihydroxyacetone in water 
results in formation of a dynamic equilibrium between dihydroxyacetone itself, its 
hydrated form and its cyclic hemiacetal dimer form.  Dissolution of dihydroxyacetone 
in acidic conditions also leads to enolization and subsequent formation of 
monohydroxyacetone and its hydrated form as evident by 1H-NMR analysis43-45.  The 
1H-NMR of the C4 lipid hydrolysis products showed overlapping peaks with that of 
DHA and sodium butyrate, indicating that the DHA lipids form the desired hydrolysis 
products (Figure 2.6(a) and (b), Figure 2.7) and (Table 2. 4(A-B)). 
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Table 2.6(a). Proton magnetic resonance chemical shifts for sodium butyrate structures 
in solution. 
 
 
A-Compound Solvent Protons δ(ppm) Peak No. 
Sodium butyrate 
 
 
D2O 
 
--CH3 
--CH2 
--CH2 
 
0.9 (t) 
1.6 (h) 
2.2 (t) 
(I) 
(II) 
(III) 
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Table 2.6(b). Proton magnetic resonance chemical shifts for di and 
monohydroxyacetone structures in solution.  
 
B-Compound Solvent Protons δ(ppm) Peak No. 
Dihydroxyacetone dimer 
 
 
D2O 
--CH2(ax) 
--CH2(eq) 
--CH2 
--OH 
3.82 (s) 
3.82 (s) 
3.7,3.9 (s) 
3.65 (s) 
(VI) 
(VI) 
(VI) 
(VI) 
Dihydroxyacetone monomer 
 
 
D2O 
 
--CH2 
--OH 
 
4.4(s) 
3.5-3.7 (m) 
(VII) 
(VI) 
Dihydroxyacetone monomer 
(hydrate) 
 
 
D2O 
 
--CH2 
--OH 
 
4.4(s) 
3.5-3.7 (m) 
(VII) 
(VI) 
Monohydroxyacetone 
 
 
D2O 
 
--CH2 
--CH3 
--OH 
 
5.25 (s) 
2.29 (s) 
3.65 (s) 
(VIII) 
(V) 
(VI) 
Monohydroxyacetone (hydrate) 
 
 
D2O 
 
--CH2 
--CH3 
--OH 
 
3.8 (s) 
1.32 (s) 
3.65 (s) 
(VI) 
(IV) 
(VI) 
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Figure 2.7. 1H-NMR spectra of (A) sodium butyrate, (B) dihydroxyacetone and (C) 
hydrolyzed C4 lipid. 
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2.3. Conclusion 
In conclusion, a family of DHA derived symmetrical lipids with varying hydrocarbon 
chain lengths were synthesized to systematically analyze how lipid chain length 
influences microparticle fabrication, microparticle morphology, and drug release 
kinetics.  Our results were somewhat surprising in that the release kinetics of a 
hydrophobic drug model increased with increasing lipid length.  SEM images, as well 
as particle density calculations collectively suggested that the microparticle porosity 
was the primary factor that controlled release kinetics, as microparticle porosity 
increased with increasing lipid length.  Future work with these lipids will focus on the 
controlled localized release of therapeutic drugs in animal models of disease. 
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CHAPTER 3 
 
SYMMETRICAL DIGLYCERIDES FOR CONTROLLED DRUG DELIVERY OF 
PROTEINS 
 3. Introduction 
In recent years, significant progress has been made in understanding the role of 
proteins and peptides in physiological and pathological processes.  However, a range 
of problems raised by their physical and chemical properties has hindered the design 
of controlled release systems for delivery of such therapeutics.  Their sensitivity to 
physical and chemical conditions as well as their short half-life requires frequent 
injection or intravenous infusion over an extended period of time, resulting in poor 
patient compliance.   
Historically, the solution to the instability problem has been to encapsulate the 
drug within a matrix to protect it from degradation and elimination; however, the 
choice of matrix is of important consideration.  Polymers have been largely considered 
the matrix of choice, especially poly(lactic-co-glycolic acid) (PLGA)-based devices.  
However, PLGA degrades into smaller chain acids upon contact with water, which can 
lead to significant drops in the environmental pH at the administration site1.  
Furthermore, protein based drugs can lose their activity during preparation procedures 
of polymeric matrices.  For example, changes in the protein structure may occur at the 
liquid-liquid interface when using organic solvents using the solvent emulsification 
technique2-7.  Protein based therapeutics often lose their activity under such harsh 
conditions, therefore use of lipid implants as parenteral drug delivery systems is a 
potential alternative for these types of drugs.   
Various types of lipids have been reported in preparation of drug-loaded 
implants.  Triglycerides in particular have been widely studied for the release of brain 
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derived neurotrophic factor (BDNF), interferon α-2a, bovine serum albumin, and 
interleukin-188-14.  In this study, we dedicate our efforts in illuminating the 
relationship between manufacturing conditions for protein-loaded implants and 
resulting matrix performance, such as release behavior and protein stability.  The 
major objectives of this present study were: (i) to prepare lysozyme-loaded, lipidic 
matrix pellets, (ii) to investigate the effect of several formulation and processing 
parameters on the resulting protein release patterns, (iii) to better understand the 
underlying mass transport mechanisms, and (iv) to be able to predict the effects of 
processing variables on the resulting drug release kinetics in a quantitative way. 
3.1. Materials and methods 
Hexadecanoyl chloride, tetradecanoyl chloride, dodecanoyl chloride, decanoyl 
chloride, ocatanoyl chloride, 1,3-dihydroxyacetone dimer 97% (DHA), anhydrous 
chloroform, anhydrous pyridine, anhydrous tetrahydrofuran, sodium borohydride, 
chicken egg lysozyme (Grade I, Mw 14 kDa) and M. lysodeikticus were all obtained 
from Sigma-Aldrich (Saint Louis, MO) and used without further purification.  
Bicinchoninic acid disodium salt (BCA) protein assay kit was obtained from 
ThermoFisher Scientific. 
3.1.1. Lipid synthesis and characterization 
Symmetrical diglycerides were synthesized through modification of a 
previously reported method by Bentley and McCrae15.  The general procedure is as 
follows, using the synthesis of C16 symmetrical lipid as an example: DHA (3.5 g, 39 
mmole) was stirred in anhydrous chloroform (150 mL) under flow of N2 at room 
temperature, followed by sequential drop-wise (1 drop/sec) addition of hexadecanoyl 
chloride (22.1 mL, 80 mmol) and anhydrous pyridine (7.5 mL), in that order (Figure 
(1A)).  The mixture was stirred for 3 hrs at room temperature, and the color varied 
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from clear to slightly yellow.  The reaction was extracted with deionized water (2 × 75 
mL), and the combined aqueous layers were washed with chloroform (1 × 75 mL).  
All chloroform layers were combined before removal by rotoevaporation in vacuo to a 
thick white/yellow residue. The residue was dissolved in dichloromethane:ether (1:1), 
in the lowest volume needed, and placed in the freezer to crystallize overnight 
(yield~70%).  The resulting product was dried in vacuo overnight and 1H-NMR was 
recorded at room temperature with a Brucker AF-300 spectrometer operating at 
300.13 MHz in preparation for the next step.  
To make the final product, lipid C16 (1,3-dihydroxypropan-2-one 1,3-
dipalmitate) (10.0 g) was dissolved in anhydrous tetrahydrofuran (250 mL) and 
benzene (50 mL) followed by the slow addition of water (15 mL).  The heterogeneous 
emulsion was cooled externally using an ice bath (temperature ~5 oC), and neutral 
sodium borohydride (1.0 g) was added to the stirring emulsion.  After 30 minutes, the 
excess sodium borohyride was reacted with glacial acidic acid (0.5 mL) by drop-wise 
addition to the reaction.  The solution was diluted with equal reaction volume of 
chloroform, washed with sodium bicarbonate (1 M) and water in that order, the 
organic layer isolated and dried over sodium sulfate.  Chloroform was removed by 
rotoevaporation in vacuo to yield a thick white/yellow residue, and further dried in 
vacuo overnight.  The characterization steps taken afterward were exactly the same to 
those taken for symmetrical lipids.  
3.1.2. Lipid matrix preparation 
The true particle density of the single materials was obtained using helium 
pyncometry measurements (Quantachrome Instruments, Boynton Beach, FL).  
Diglyceride powders were ground and sieved using 200 µm USA standard sieves 
(Fisherscientific) and lyophilized for at least 24 hrs to remove excess moisture.  The 
 49 
binary mixtures of protein and diglyceride powders were combined carefully using 
geometric dilution.  Protein loaded implants were prepared by using a hydraulic press 
(Carver, Model No. 3851-0, Wabash, IN) with a pressure gauge.  The following 
protein loadings (1, 5 and 10%) and lipids were mixed geometrically in an agate 
mortar.  The final powder mixture was compressed using a range of different 
pressures, first batch implants were compressed using 0.25 Ton force over 10 seconds, 
and second batch implants were compressed using 0.25 Ton force over 10 seconds, 
followed by gradual increase of force to 0.5 Ton force for an additional 10 seconds.  
For clarity, from here on the first batch is referred to as group A and second batch is 
referred to as group B.  Implants were compressed under a range of different forces to 
achieve a controlled series of porosities, and cylinder heights were measured (n=3) 
using a digital sliding caliper (Marathon, Part No. CO030150).  Porosity ε was 
calculated by the eq. 1 adapted from Siegel et al 16. 
 
                                                            (1) 
where L is the protein loading, W is the mass of the implant, V denotes the volume 
calculated from Caliper measurements and ρ was obtained using helium pyncometry 
measurements (Quantachrome Instruments, Boynton Beach, FL).  For the in vivo 
biocompatibility study, lyophilized and sieved lipid powder was compressed by 
applying a pressure of 0.5 tons over 10 seconds to produce 50 mg implants of 5 mm 
diameter.  The implants were sterilized using UV irradiation on each side for 30 
minutes.  
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3.1.3. Quantification of model substance release 
3.1.4. In vitro release study 
Lipid implants were incubated in 1.0 mL phosphate buffer saline pH 7.4 at 37 
oC.  Buffer was removed and replaced completely after each sampling interval and 
stored at -20 oC until further analysis.  Bicinchoninic acid disodium salt (BCA) protein 
detection kit (FisherThermoscientific) was used to determine protein concentration in 
the release buffer through mixing of 25 µL of samples with 200 µL of working 
solution.  The samples were mixed thoroughly for 30 second and incubated at 37 oC 
for 1 hr, after which the absorbance was measured at λ=562 nm using a microplate 
spectrophotometer (Spectramax GeminiEM; Molecular Devices, Sunnyvale, CA).  
3.1.5. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
The protein released from the implants was analyzed using SDS-PAGE after 
the following time points: 2, 24, 168 and 288 hrs. All of the gels were run under 
reducing conditions.  Each sample was mixed with an equal volume of sample buffer 
SDS (1% w/v), Tris-HCl (pH 6.8, 0.06 mM), glycerol (3 mM), bromophenol blue 
(0.01% w/v), and β-mercaptoethanol (0.05% v/v)).  The samples were boiled for 5 
minutes and cooled to room temperature before loading onto the gel.  The samples 
were then resolved through a 4-18% polyacrylamide gradient gel at a constant voltage 
(125 V).  Prestained molecular weight standards (BioRad Kelidoscope Precision Plus) 
were used to estimate the molecular weight of each protein sample.  The gels were 
stained with Coomassie Blue dye and then photographed.  The apparent molecular 
weights of the stained bands were then compared to that of the standards. 
3.1.6. Biological activity of lysozyme  
M. lysodeikticus (0.01%, w/v) was suspended in potassium phosphate buffer 
(66mM, pH 6.24).  A 0.1 mL aliquot of appropriately diluted lysozyme samples was 
mixed with 2.5 mL of prepared M. lysodeikticus suspension in a quartz cell (path 
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length 1 cm), which was then immediately placed into a spectrophotometer 
(SpectraMax).  The rate of decrease of absorbance at 450 nm was monitored by the 
UV spectrophotometer during a total period of 3 minutes at 25oC.  The slope of the 
linear portion in the plot of absorbance against time provided the amount of lysozyme 
in enzyme unit (EU) 10, 17, 18. Units of active lysozyme were calculated based on the 
EU, using eq. (2-3): 
 
(2-3) 
 
 
In the equation, df was the dilution factor and 0.001 was from the definition of 
lysozyme unit as one unit will produce ΔA450 nm of 0.001 per minute at pH 6.24 and 
25oC using a suspension of M. lysodeikticus as substrate in a 2.6 mL reaction mixture.  
The volume in milliliter of lysozyme sample used 0.1 mL.  The biological activity of 
the released lysozyme sample was then compared with the native lysozyme sample to 
evaluate the effect of formulation on its biological activity.  
3.1.7.  In vivo biocompatibility and erosion studies 
This study was conducted in accordance with the Cornell University 
Institutional Animal Care and Use Committee.  The model animals were 8 weeks old 
female Sprague-Dawley rats  (Harlan Sprague-Dawley, Inc. Indianapolis, IN).  A total 
of 96 rats (4 per time point per group) were used for this study.  Rats were weighed 
and pre-medicated using buprenorphine HCl (0.01 mg/kg s.q.) 20 minutes prior to 
anesthetic induction.  Anesthesia was induced using isoflurane (2-3%) in oxygen via 
facemask and maintained through the surgical procedure (1-3% isoflurane in oxygen 
via face mask).  Vital signs including heart rate and respiratory rate, as well as 
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response to stimulation and pedal reflex, were monitored throughout the anesthetic 
period. After induction, the dorsal intrascapular area was clipped and prepared using 
2% chlorhexidine gluconate in standard aseptic technique.  
Animals were divided into 6 groups of 16 animals each: control (sham surgery 
without implant placement), C10, C12, C14, C16, and PLGA. For surgery, standard 
aseptic technique was used.  A 0.5 cm stab incision was made over the dorsal border 
of each scapula, 0.5 cm lateral to midline bilaterally.  A small subcutaneous pocket 
was created using blunt dissection and the implant was placed. The incision was 
closed using 4-0 nylon. 
The animals were allowed to recover in their cages and were monitored for 
pain, suture removal, or other adverse side effects every 2 hours the day of surgery and 
twice a day thereafter.  All rats were housed two per cage in a temperature and 
humidity controlled room with a 12-hour on-off light cycle in accordance with the 
standard procedures.  Rats in each group were euthanized on days 2, 7, 14, and 28 
after surgery using pentobarbital sodium (0.4-0.75 mL) intraperitoneally.  Immediately 
after euthanasia, a necropsy was performed.  One of the implants and its surrounding 
tissues were randomly chosen, and representative samples of the liver, spleen, kidney, 
and lungs were also harvested and placed into 10% buffered formalin.  The second 
implant site was also removed and weighed for in vivo water uptake and inspected for 
in vivo erosion study.  The samples were shipped in formalin via overnight carrier to 
Brigham and Woman’s Hospital-Boston for histopathology.  The pathologist was 
blinded to the treatment groups. 
To determine the degree of in vivo erosion, the excess tissue surrounding the 
retrieved implants were cleaned off as much possible and samples were dried under 
vacuum and weighed.  The mass loss of an implant relative to its original weight was 
taken as a measure of erosion. 
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3.1.8.  Tissue embedding, sectioning and staining 
The harvested implants and the surrounding tissue were dehydrated through a 
series of graded ethanols and xyelen, and embedded in paraffin using standard 
histological technique.  The samples were sectioned to a thickness of 5µm and stained 
with hematoxylin and eosin to reveal the histologic details. 
3.1.9.  Theory 
 Drug release was described using Fick’s second law of diffusion, considering 
axial as well as radial mass transfer in a cylinder of a finite length, 
 
         
   (2) 
where c is the concentration of the drug; t represents time, r,z denote the radial and 
axial coordinates and θ the angle perpendicular to the r-z plane; D represents the 
apparent diffusion coefficient of the drug within the implant. Using infinite series of 
exponential functions this partial differential equation can be solved assuming initial 
boundary condition of homogenous drug distribution at t=0 (before the exposure to the 
release medium) and perfect sink conditions, leading to19: 
 
          (3) 
 where Mt and M∞  represent the absolute cumulative amounts of drug released at time 
t, and infinite time, respectively; qn are the roots of the Bessel function of the first kind 
of zero order [Jo(qn)=0], and R and H denote the radius and height of the cylinder.  
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3.2.  Results and Discussion 
The symmetrical diglycerides were successfully synthesized following the 
modified Schotten-Baumann acylation, and were further characterized in terms of 
physical and chemical characteristics, Scheme 3.1 and Table 3.1.  All of the 
synthesized diglycerides have melting points that are above room temperature and 
body temperature, making them ideal candidates for fabrication into implants for 
controlled drug delivery.  Elemental analysis obtained for C10-C16 diglycerides is 
summarized in Table 3.1.  A representative NMR spectrum of C14 diglyceride is 
shown in Figure 3.1.  The 1H-NMR peaks for the all lipid in increasing carbon number 
are: 1H-NMR(300MHz, CDCl3, δ): [C10 diglyceride], 0.86(t, 6H), 1.25 (s, 28H), 2.27 
(t, 4H), 4.13 (m, 6H), [C12 diglyceride], 0.86(t, 6H), 1.25 (s, 36H), 2.27 (t, 4H), 4.13 
(m, 6H), [C14 diglyceride], 0.86(t, 6H), 1.25 (s, 48H), 2.27 (t, 4H), 4.13 (m ,6H), [C16 
diglyceride] 0.86 (t, 6H), 1.25 (s, 52H), 2.27 (t, 4H), 4.13 (m, 6H). 
As mentioned in chapter 2, each symmetrical diglyceride is abbreviated as Cx where 
“x” is an indication of the number of carbons available on either side chain. 
 
Table 3.1. Melting point and elemental analysis of solid diglycerides 
Theoretical Elemental 
Analysis 
Experimental Elemental 
Analysis Lipid 
Melting 
point 
(oC) %C %H %C %H 
C10 Diglyceride 43.05 68.69 11.07 68.88 11.17 
C12 Diglyceride 57.10 71.01 11.48 71.04 11.57 
C14 Diglyceride 61.88 72.61 11.79 72.52 12.01 
C16 Diglyceride 69.41 73.89 12.05 74.15 12.29 
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Scheme 3.1. Reaction pathway for the synthesis of symmetrical 1,3-diglycerides 
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Figure 3.1.1H-NMR spectra of C14 lipid (2-hydroxy-3-(tetradecanoyloxy)propyl 
pentadecanoate). This spectrum serves as a representative of the remaining 
diglycerides. 
 
 
                  Scheme 3.2. Preparation of lipid implant through direct compression 
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3.2.1.  Controlled release of lysozyme 
The helium pyncometry measurements of diglyceride powders showed that 
they have similar densities, thus according to eq. (1) porosity of the same size implants 
is not a function of the lipid type, Table 3.2.  
 
Table 3.2. True density results of He-pyncometry 
 
Diglyceride C10 C12 C14 C16 
Density (g/mL) 1.0334 1.042 1.0225 1.0031 
 
Our results showed that the diglyceride had a direct impact on the resulting 
release behavior of the model protein lysozyme, Figure 3.2-3.3.  The amount of 
protein released over time decreased in the same order as the fatty acid chain length in 
the matrix increased.  Studies have shown that drug release is a function of surface 
energy and thus matrix wettability 19, 20.  In the case of lipids, the longer fatty acid 
chain length leads to lower the overall wettability of the matrix.  However, wettability 
can change during compression, moreover the surface roughness and penetration of 
the wetting liquid can distort the results.  Therefore while wettability is a determining 
factor in onset of the release, the release behavior becomes more complex as wetting 
liquid penetrates further toward the center of the matrix.  
3.2.2.  Effects of drug loading 
The effects of the initial lysozyme loading on drug release from diglyceride-
based implants prepared by direct compression method are shown in Figures 3.2-3.3.  
An increase in the drug loading from 1 to 10% (w/w) resulted in a significant increase 
in the release rate, however all implants showed dramatic burst effect.  This can be 
attributed to increase in lipid matrix porosity upon protein release.  This effect is more 
pronounced at higher drug loadings (5-10%).  Increased matrix porosity lead to higher 
drug mobility and thus an overall increase in absolute and relative release rates.  It is 
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worth mentioning that the release rate was affected by initial drug loading as well as 
the underlying release mechanism.  The drug release rate is primarily controlled by 
diffusion for lower drug loadings whereas for higher drug loadings (5-10%), the 
diffusion-controlled model systematically fails to fully describe the release 
mechanism.  Upon contact with release medium, lysozyme starts to leach out of the 
matrix, resulting in increased matrix porosity and thus increased drug mobility.  The 
increase in drug mobility compensates for the increase in the length of diffusion 
pathway. 
3.2.3.  Effects of the compression force 
To address the effect of different porosities within the diglyceride resulting 
from different compression behavior, diglyceride powders were compressed under a 
range of different pressures to achieve a controlled series of porosities.  Siegel et al16 
hypothesized that release from a monolithic matrix happens through a porous network 
of tortuous path created by drug particles.  At high loading, the drug forms a complete 
interconnected network of its own, and release is a function of dissolution and 
diffusion through this network. Increased loading provides simpler pathways (low 
tortuosity) and greater porosity for diffusion21.  At low loading, incomplete 
interconnected networks are formed and therefore release is incomplete although a 
burst release is observed because of dissolution of drug particles on the surface of the 
matrix. 
 Our results also indicate the burst effect in the early hours of the experiment, 
however it is possible that the burst effect is a result of low compression and 
subsequently low cohesion between the diglcyeride and drug particles, ultimately 
resulting in insufficient structural integrity of the implants when placed in the buffer.  
Higher drug loadings for both groups of A and B also showed burst effect and an 
overall faster release rate due to formation of the porous drug particle network.  The 
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study outcome showed that for lower drug loading (1%), increasing compression force 
results in formation of less porous matrices and thus slower release rates, however for 
higher drug loadings (5-10%), increasing compression force does not significantly 
improve release behavior (Figure 3.4(a-c)).  An interesting outcome in the study of the 
effect of compression force on release behavior was the apparent increase in 
brittleness of the implants. Increasing compression force resulted in formation of 
easily friable implants, particularly in case of C10-C14 diglycerides with high 
lysozomal loading, (Figure 3.2.).  
 To better understand the underlying mass transport mechanism controlling 
lysozyme release from diglyceride implants, an analytical solution of Fick’s second 
law of diffusion was fitted to the experimentally determined lysozyme release kinetic.  
Based on these calculations, the apparent diffusion coefficient of lysozyme released 
from diglyceride implants could be determined (Figure 3.5.).  The gradual increase in 
diffusion coefficient allows us to assume that the buffer penetrates the implant through 
the submicron spaces between the lipid plates and drug release occurs via diffusion 
through these buffer filled channels.  Thus the structure of this submicron void 
network determines the release pattern. 
 
Figure 3.2. Increasing compression force results in friable implants, particularly in 
case of C10-C14 diglycerides with high lysozomal loading.
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Figure 3.3(a). Lysozyme release behavior from lipid implants prepared with lower 
compression force with 1% lysozyme loading. Shorter chain diglycerides show faster 
release compared to more hydrophobic diglycerides. Increasing the drug loading also 
causes an increase in over release rate and shows immediate burst effect. 
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Figure 3.3(b). Lysozyme release behavior from lipid implants prepared with lower 
compression force with 5% lysozyme loading Shorter chain diglycerides show faster 
release compared to more hydrophobic diglycerides. Increasing the drug loading also 
causes an increase in over release rate and shows immediate burst effect. 
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Figure 3.3(c). Lysozyme release behavior from lipid implants prepared with lower 
compression force with 10% lysozyme loading Shorter chain diglycerides show faster 
release compared to more hydrophobic diglycerides. Increasing the drug loading also 
causes an increase in over release rate and shows immediate burst effect. 
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Figure 3.4(a). Lysozyme release behavior from lipid implants prepared with higher 
compression force with 1% lysozyme loading. Similar to group A, shorter chain 
diglycerides show faster release compared to more hydrophobic diglycerides, and 
increasing the drug loading also causes an increase in over release rate and shows 
immediate burst effect. Increasing the compaction force does not improve release 
behavior and burst effect appears to be more significant compared to group A. 
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Figure 3.4(b). Lysozyme release behavior from lipid implants prepared with higher 
compression force with 5% lysozyme loading. Similar to group A, shorter chain 
diglycerides show faster release compared to more hydrophobic diglycerides, and 
increasing the drug loading also causes an increase in over release rate and shows 
immediate burst effect. Increasing the compaction force does not improve release 
behavior and burst effect appears to be more significant compared to group A. 
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Figure 3.4(c). Lysozyme release behavior from lipid implants prepared with higher 
compression force with 10% lysozyme loading. Similar to group A, shorter chain 
diglycerides show faster release compared to more hydrophobic diglycerides, and 
increasing the drug loading also causes an increase in over release rate and shows 
immediate burst effect. Increasing the compaction force does not improve release 
behavior and burst effect appears to be more significant compared to group A. 
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Figure 3.5. (Top) Apparent diffusion coefficient of lysozyme released from 
diglyceride implants. Burst release behavior from diglyceride implants C14 and C12 is 
noted with diffusion coefficients of order of 10-7 cm2/s, C16 , C10 and PLGA show 
diffusion coefficient of order of 10-9 cm2/s, (bottom) burst release behavior of C16 
diglyceride implants with 5-10% lysozomal loading. 
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3.2.4.  Influence of processing condition on protein stability 
 Released lysozyme from groups A and B were tested for structural integrity 
(Figures 3.5-3.6) and specific enzyme activity and compared with native lysozyme, 
(Figures 3.7-3.8)17, 18, 20.  SDS-gel electrophoresis was used to test the stability of the 
protein structure, the resulting protein bands appeared alongside the control lysozyme 
band, suggesting that protein was not degraded or aggregated in the formulation step.  
The direct compression method seems to have small impact on the structural integrity 
of the lysozyme, (Figure 3.6-3.7).  Enzymatic activity was tested using M. 
lysodeikticus suspensions in potassium phosphate buffer.  Results indicated a 
decreased in enzymatic activity as time progresses possibly due to aggregation, 
especially with high lysozomal content (5-10%).  Additionally, during compaction, the 
protein molecule is subjected to both pressure and shear (and possibly heat) that could 
result in reversible or irreversible denaturation.  Interestingly, lysozyme released from 
C16 diglyceride implants showed higher enzymatic activity in comparison to other 
diglyceride, possibly due to lower wettability characteristics.  
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Figure 3.6. SDS-gel electrophoresis of protein present in release buffer, group A. Time 
points were 2hr, 24hr, 120hr and 228 hr after the start of the release experiments. 
Native lysozyme with molecular weight 14kDa was used as a control, (A) C10, (B) C12, 
(C) C14, (D) C16 and PLGA bands are shown. The proteins showed minimal 
aggregation compared to the native, un-encapsulated lysozyme.
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Figure 3.7. SDS-gel electrophoresis of protein present in release buffer, group B. Time 
points were 2hr, 24hr, 120 and 228 hrs after the start of the release experiments. 
Native lysozyme with molecular weight 14kDa was used as a control, (A) C10, (B) C12, 
(C) C14, (D) C16 and PLGA bands are shown. Similar to group A, the proteins showed 
minimal aggregation compared to the native, un-encapsulated lysozyme.
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Figure 3.8. Enzymatic activity testing using M. lysodeikticus suspensions for group A 
revealed that the activity decreases with increasing time, possibly due to aggregation 
within lipid implants. Increasing lysozomal loadings seems to decrease the enzymatic 
activity of the proteins, possibly due to shear compaction forces and induced heat 
during processing. 
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Figure 3.9.  Enzymatic activity testing using M. lysodeikticus suspensions for group B 
also showed that the activity decreases with increasing time, possibly due to 
aggregation within lipid implants.  
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3.2.5.  In vivo biocompatibility and in vivo erosion 
In vivo biocompatibility of the diglyceride implants was evaluated in female 
Sprague-Dawley rats after subcutaneous administration.  Figure 3.10 shows images of 
subcutaneous histology of poly(lactic-co-glycolic acid) implant that was prepared 
under the exact conditions and used as a positive control, in addition to the existing 
negative control.  None of the animals died unexpectedly, exhibited abnormal 
behavioral changes, or experienced obvious weight loss, suggesting no gross toxicity 
from the surgical procedures or from the implants.  An acute inflammatory type 
response was observed for the 2-day and 7-day time points, characterized by increased 
permeability of the capillaries and presence of foreign body giant cells (FBGC) and 
formation of granulomas.  The 14-day and 28-day samples displayed minimal fibrosis 
and the presence of thin fibrous capsule. To understand the in vivo erosion behavior of 
these materials, changes in implant weight was recorded and plotted against lipid type 
and time, (Figure 3.10-3.11).  Low wettability diglycerides such as C16 and C14 
displayed less in vivo erosion compared to more hydrophilic C10 and C12.  The longer 
chain diglyceride were less water-soluble thus significant in vivo erosion was not 
observed until later time points in the study.  Overall results of the study showed 
minimal fibrosis, no muscle damage, or necrosis, indicating the acceptable 
biocompatibility of the diglyceride delivery systems. 
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Figure 3.10. In vivo biocompatibility of the diglyceride implants showed increased 
permeability of the capillaries and presence of foreign body giant cells (FBGC) and 
formation of granulomas compared to PLGA control implant.  Histology results of (a) 
PLGA, (b) C10 diglyceride, (c) C12 diglyceride, (d) C14 diglcyeride, (e) C16 diglyceride, 
after 14 days time point. . Arrows mark the tissue-implant interface.The magnification 
on this slide is 100X. 
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Figure 3.11. In vivo erosion of diglyceride implants with PLGA as control. Results 
showed that more hydrophobic lipids show slower in vivo erosion compared to more 
hydrophilic lipids, high in vivo erosion at 28 days time points is possibly due to 
formation of fibrous capsule around implants.                              
3.3.  Conclusion 
Wettability effects often play a crucial role in release of high molecular weight 
model compounds from lipidic matrices.  Thus release behavior of proteins can be 
tailored by varying the lipophilicity of the matrix material via selectively varying the 
fatty acid chain length.  The symmetrical diglycerides showed excellent properties for 
retaining physical and chemical characteristics of the model compound, however the 
burst effect in release behavior limits their use for prolonged drug release applications.  
The burst release, possibly due to less than desirable mechanical properties of 
diglyceride powders can be remedied through forming blends with other lipids such as 
cholesterol.  The biocompatibility of diglycerides implants in rats showed acute 
inflammatory response however implants for earlier time points showed no sign of 
tissue necrosis or damage.  Further work with the diglycerides will focus on achieving 
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a better understanding of their mechanical behavior and its effect on the release of 
macromolecules. 
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CHAPTER 4 
 
FUTURE DIRECTIONS 
4. Introduction 
A considerable amount of research has been carried out in the past few years in 
order to obtain novel biomaterials with improved specific properties for controlled 
drug delivery. Lipids and in particular triglycerides, have gained growing attention in 
this context due to their desirable properties: as physiological substances they have 
displayed good biocompatibility subcutaneously, and in brain; they are easily 
compactable and display long term stability during storage, thus marking this group of 
materials as strong alternatives to polymeric matrices1-4. Diglycerides in return have 
received attention as matrix blends and participants in binary matrices, therefore a 
through study of their potential as single component monolithic matrices remains to be 
done5, 6.   
We investigated the potential of symmetrical 1,3-lipids and their glyceride 
analogs as matrices for controlled drug delivery applications. We synthesized a family 
of DHA derived symmetrical lipids with varying hydrocarbon chain lengths to 
systematically analyze how lipid chain length influences device fabrication, its 
morphology, and the resulting drug release kinetics. Our study showed that wettability 
effects often play a crucial role in the release of high molecular weight model 
compounds from lipidic matrices. Thus release behavior of proteins from lipid 
matrices, can be tailored by varying the lipophilicity of the matrix material via 
selectively varying the fatty acid chain length. The symmetrical diglycerides showed 
excellent properties for retaining physical and chemical characteristics of the model 
compound, however the burst effect in release behavior may limit their use for 
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prolonged drug release applications. The burst effect is possibly due to structural 
integrity of the implants, thus the future work of this study would benefit from 
focusing on mechanical characterization of diglycerides for compaction and tabletting 
to improve release behavior, in addition to quantitative measurements of pore size and 
distribution within the matrix. 
4.1.  Mechanical characterization of diglyceride powders 
Successful compaction and tabletting of powders requires a full understanding 
of fundamental mechanical properties of powders, which dictates how formulations 
will behave during compaction.  During the tabletting process, powders go through 
initial packing and rearrangement of particles, formation of temporary structures, 
elastic deformation, plastic deformation followed by breakage of particles, bond 
formation and consequently elastic recovery during the decompression process7. The 
deformation characteristics may be elastic, plastic, brittle fracture or a combination of 
these mechanisms.  The factors that determine the deformation behavior also include 
Young’s modulus, yield stress, and fracture toughness. However, deformation 
behavior of powder is predominantly a function of applied stress.  Thus a study of 
stress-strain behavior of tablets can provide more information on a powder’s response 
to mechanical stress. 
4.2.  Porosity measurements as a function of compression force 
Porosity is a measure of void spaces in a material and can be evaluated using a 
variety of techniques such as density, gas adsorption, water displacement and 
porosimetry8, 9. Quantitative measurements of pore size and distribution can provide 
invaluable insight into disintegration, dissolution, adsorption and diffusion of drugs.  
The gas adsorption method is limited to pore diameters less than 2000 oA, thus 
mercury porosimetry, is the most suitable method for measuring the pore size. This 
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method is based on intrusion of mercury into the pores of a solid sample and it is 
explained using the Washburn equation:  
 
       (1) 
where P the pressure (psia), r is the pore radius (µm), γ is the surface tension of the 
mercury (dynes⋅cm-1), and θ denotes the contact angle of the mercury. Mercury 
penetration under pressure, determines the size and quantity of the void spaces and 
pores. Additionally, decreasing pressure causes mercury to expel from the pores when 
therefore providing information on pore shape and structure 8, 9. 
4.3.  Summary 
The mechanical characterization of these biomaterials would provide 
invaluable information regarding the intrinsic physical properties of symmetrical 1,3-
diglycerides. The initial demonstration of release behavior of model drugs from these 
biomaterials combined with the additional insight into their behavior provides the 
ground for exploring further scientific opportunities in controlled release. 
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APPENDIX A 
 
SOLID LIPID MICROPARTICLES’ CHARACTERIZATIONS 
A.  Introduction 
A.1.  Controlled release drug delivery-Polymeric systems 
The goal of controlled drug delivery is to develop a system that delivers drugs 
in a predictable and effective manner 1-4.  Various synthetic and natural materials such 
as polymers, cyclodextrins, and lipids have been investigated (i.e. poly(lactic acid-co-
glycolic acid), polyanhdyrides, collagen, polysaccharides).  In recent years the focus 
of drug delivery has shifted toward lipid based formulations despite the ubiquitous 
presence of polymers in this field 5-31.  Polymers present specific obstacles for 
pharmaceutical development.  A manufactured drug needs to be homogenous and 
consist of one species.  In contrast polymers by nature are heterogeneous, thus as 
macromolecules they present specific characterization challenges.  The average 
molecular weight of a polymer is described as ‘weight average molecular weight’ 
(Mw), and ‘number average molecular weight’ (Mn).  The ratio of these two 
parameters (Mw/Mn) gives a measure of polydispersity (PDI), meaning that a 
particular polymer sample may contain individual molecules of various chain lengths 
resulting in less than optimal conditions.  The presence of a distribution of molecular 
weights directly impacts the kinetics of drug delivery and introduces variability 
amongst batches [5].  
A.2.  Lipid-based drug delivery systems 
Lipids circumvent the difficulties associated with achieving a narrow 
polydispersity when it comes to chemical synthesis, inadvertently reducing the batch 
to batch variability.  Previous results highlighting lipids as excipients or prodrugs set 
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the stage for further investigation of lipid-derived systems 13-16, 26-31.  Our aim for this 
project is to design a lipid-derived drug delivery vehicle for which the rate of release 
of the drug correlates with the level of hydrophobicity of the vehicle. In doing so, our 
goal is twofold.  First to synthesize biomolecules with varying degrees of 
hydrophobicity with dihydroxyacetone (DHA) as a starting material, second to take 
advantage of the physical nature (i.e. solid, liquid) of these biomolecules for various 
controlled release drug devices (i.e. microparticles, implants, injectable depots). 
Here we report the synthesis of a series of bioinspired symmetrical lipids, 
comprised of two classes of biomolecules, fatty acids and dihydroxyacetone (DHA).  
DHA a constituent, of the glycolysis pathway, and is FDA approved for oral and 
topical administration, making it an attractive building block for new biomaterials 34-
37.  The particular advantage of using DHA as a lipid building block for this study is 
that the strong dipole moment of the DHA carbonyl maintains the lipids in the solid 
state while the lipids lengths are varied. In fact the further synthesized symmetrical 
glycerol analogues of the lipids are in liquid form.  The solid state of the DHA lipids 
allows their use as microparticles or implants, and the liquid state of the glycerol 
analogs makes room for use as injectable formulations. 
A.3.  Applications of solid lipids 
Microparticulates are used in the pharmaceutical field as injectable systems to 
control the spatial and temporal release of drugs 3-4,10-11.  Historically, materials that 
comprise the microparticle matrix are composed of synthetic polymers such as 
poly(lactic-co-glycolic acid), and the polyanhydrides, or natural polymers such as 
collagen, gelatin and chitosan.  These materials have been successfully marketed in 
devices for controlled drug release systems.  Recently, solid lipids have emerged as a 
new class of material that may be suitable for microparticle-based controlled drug 
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delivery 13-20.  A number of solid lipids are reported, such as fatty acids and alcohols, 
as well as the mono-, di- and tri-esters of glycerol [17, 26].  These reports support the 
potential use of solid lipids for the delivery of hydrophobic and hydrophilic small 
molecules, as well as the controlled release of peptides and proteins.  Although the 
solid lipid matrix literature is fairly extensive, there has yet to be a systematic 
investigation of how the lipid matrix can be engineered at the molecular level to 
modulate the functional characteristics of the microparticle.  Specifically, there is little 
understanding of how lipid structure, particularly lipid length, influences microparticle 
fabrication, microparticle morphology, and drug release kinetics. 
Few studies exist on the use of saturated diglycerides alone as drug delivery 
vehicles.  Lipid based delivery systems range from simple oil solutions to complex 
mixtures of oil, surfactants, cosurfactants and cosolvents, also described as 
microemulsions.  However most of the studies have focused on the use of triglycerides 
or lipids with complex phase behavior 23, 26. Earlier results obtained have shown that 
bioavailability of poorly water soluble drug is significantly enhanced when 
administered with food rich in fat. Diglyceride prodrugs of ibuprofen and an HIV 
protease inhibitor have also been reported 27-28. Diglycerides are overlooked as liquid 
hydrophobic matrices for controlled drug delivery in lipidic systems, noting their 
dissolution abilities encompass a wide range of hydrophobic and highly hydrophobic 
drugs. 
This study describes the synthesis and characterization of symmetrical lipids 
and their glyceride analogs with incrementally increasing aliphatic lipid tails, their 
application as drug delivery vehicles, and the investigation of how the hydrophobicity 
influences controlled release kinetics of a model drug compound.  The first part of this 
report describes the experimental design and results associated with solid lipid 
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microparticles; the second part illustrates the experimental approach toward synthesis 
and characterization of liquid hydrophobic matrices derived from solid lipids. 
B. Solid lipid microparticles for controlled drug delivery 
B.1.  Materials and methods 
Hexadecanoyl chloride, tetradecanoyl chloride, dodecanoyl chloride, decanoyl 
chloride, ocatanoyl chloride, 1,3-Dihydroxyacetone dimer 97% (DHA), chloroform, 
anhydrous pyridine and nile red were all obtained from Sigma-Aldrich (Saint Louis, 
MO) and used without further purification. Poly(vinyl alcohol) (PVA, MW∼25,000, 88 
mole% hydrolyzed) was purchased from Polysciences Inc. Dichloromethane (DCM), 
acetone, tetrahydrofuran (THF) and diethyl ether were purchased from J.T.Baker 
(West Chester, PA).  All reagents and solvents were used as received without 
additional purification. 
B.2.  Lipid synthesis 
1,3-dihydroxypropan-2-one 1,3-dialkylate  
 Symmetrical lipids were synthesized through modification of a previously 
reported method by Bentley and McCrae 39.  The general procedure is as follows, 
using the synthesis of C16 symmetrical lipid as an example: DHA (3.5 g, 39 mmole) 
was stirred in anhydrous chloroform (150 mL) under flow of N2 at room temperature, 
followed by sequential dropwise (1drop/sec) addition of hexadecanoyl chloride (22.1 
mL, 80 mmol) and anhydrous pyridine (7.5 mL), in that order.  The mixture was 
stirred for 3 hrs at room, and its color varies from clear to slightly yellow due to 
dihydroxyacetone degradation.  The reaction was extracted with deionized water (2 × 
75 mL), the organic layers from each wash were combined and the combined aqueous 
layers were washed with chloroform (1 × 75 mL). All chloroform layers were 
combined before removal by rotoevaporation in vacuo to a thick white/yellow residue.  
The residue was dissolved in dichloromethane:ether (1:1), in the lowest volume 
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needed, and placed in the freezer to crystallize overnight.  Melting points were 
collected on a Fisher-Johns melting point apparatus.  1H-NMR spectra were recorded 
at room temperature with a Brucker AF-300 spectrometer operating at 300.13 MHz, 
and elemental analyses were obtained through QTI (Whitehouse, NJ).  
B.3.  Fabrication of solid lipid microparticles (SLM) by the spontaneous 
emulsification 
Each lipid (0.1 gm) was dissolved in a 3:2 (v:v) ratio of DCM:acetone by 
vigorous vortex for approximately 10 seconds. The lipid solution was transferred 
using a glass pipet into a stirring PVA solution as a slow and steady stream (450 mL, 
2.5%).  The suspension was stirred for 3 hrs to allow evaporation of the organic 
solvents and hardening of the microparticles.  Microparticles were isolated by 
centrifugation at 4,800 RCF for 60 minutes followed by multiple washes (3×) with 
deionized water and re-centrifugation at 4,800 RCF for 45 minutes.  The particles 
were resuspended in small volumes of deionized water and lyophilized for a minimum 
of 12 hrs and were stored at -20 °C in the presence of desiccant.  The final products 
were fine powder particles with approximate yield of 75% (relative to original weight 
of lipid). 
B.4.  Particle characterization 
The solid lipid microparticles were analyzed by two different methods to 
determine their geometric and aerodynamic size distributions.  All measurements 
assume spherical geometry.  The size distributions of each sample were collected until 
there were no changes in the overall shape of the distribution curve. For each method, 
the total number of counted particles was >10,000.  Geometric sizes of lipid particles 
in powder form were determined in isotonic diluent (Isoton II) by a Coulter Multisizer 
III (Beckman Coulter Inc.) equipped with a 100 µm aperture.  About 5 mg of a given 
powder sample was added to 20 mL of Isoton II and each suspension was shaken for 
 87 
one minute to deagglomerate the particles. Any bubbles were allowed to dissipate 
prior to measurement.  Aerodynamic size distributions of the particles were 
determined directly from powder samples via time-of-flight measurements using an 
Aerosizer LD (Amherst Instruments) with a 700 µm aperture assuming a material 
density of 1 g/cm3. About 5 mg of sample was introduced to the apparatus, and subject 
to a pneumatic shear force of 2 PSI. All cavities in the apparatus were cleaned with 
compressed air after each run so that the overall count within a minute of empty 
performance was reduced to <100.  
Particle morphology was studied at low voltage (5 kV) using scanning electron 
microscopy imaging (LEICA 440) after coating with palladium.  Surface charge on 
samples suspended in 1:10 diluted PBS were measured using a Malvern Zetasizer-
Nano ZS (Malvern, UK).  A PRECO Hydraulic press (Los Angles, CA) was used to 
make lipid pellets with approximate surface area of 25 mm2.  For contact angle 
measurements, a ramé-hart contact angle goniometer (100-FO) was used to measure 
the sessile contact angle of water on a lipid pellet surface. Unless otherwise stated, 
measurements were conducted in triplicate.  
B.5.  In vitro drug release and model drug distribution 
The encapsulation efficiency of lipid microparticles was determined via 
complete drug recovery from dissolved microparticles, followed by comparison with 
the theoretical maximum drug loading.  Microspheres (5 mg) were dissolved in 
acetonitirile:THF  (1 mL ) and nile red concentration measured by UV absorbance at 
λ=535 nm  using  a microplate spectrofluorometer (Spectramax GeminiEM; 
Molecular Devices, Sunnyvale, CA). In vitro release kinetics were determined by 
suspending 5.0 mg of microspheres in 1- mL of PBS in amber microcentrifuge tubes 
(Eppendorf) and incubating at 37 °C under gentle rotation. The supernatant was 
collected in total for fluorescence measurement after certain time intervals to 
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determine the amount of release, and replenished with fresh buffer.  Nile red 
concentration was measured at λEx= 550 nm and λEm=650 nm quantified according to 
a standard curve.  Distribution profiles of nile red within lipid microparticles were 
obtained by laser confocal microscopy (Leica TCS SP2) with a helium-neon laser 
excitation source (543 nm).  Samples were placed on microscope slides and sealed 
with cover slips.  Fluorescence intensity profiles were determined with image analysis 
software (Image J). 
B.6.  Nomenclature 
IUPAC nomenclature for the symmetrical lipids is of the form, using the 
octanoic acid lipid as an example, octanoic acid 3-octanoyloxy-2-oxo-propyl ester.  To 
improve the readability of the text, each symmetrical is abbreviated Cx where “x” 
denotes the number of carbons in the corresponding fatty acid. 
B.7.  Statistical Analysis 
 The statistical significance of experimental results was determined using the 
two sample Students’ t-test with significance set to samples with p<0.05. The 
calculated errors were set to standard mean error for all experimental results. 
C.  Results and Discussion 
A series of symmetrical lipids were successfully synthesized by Schotten-
Baumann acylation following the method of Bentley and McCrae with yields in excess 
of 70% 39 (Scheme C.1).  The acyl chlorides were chosen such that the final product 
was derived from physiological lipids; for example palmitoyl chloride (IUPAC: 
hexadecanoyl chloride), derived from hexadecanoic acid, was selected to synthesize 
lipid C16.  In addition, all of the synthesized lipids have melting points that are above 
room and body temperature, making them good candidates for fabrication into solid 
 89 
microparticles for controlled drug delivery.  Elemental analysis obtained for C8-C16 
lipids are summarized in Table C.1.  
 
 
 
 
Table C.1. Elemental analysis of symmetrical solid lipids 
 
 
 
 
 
Figure C.1. 1H NMR (300 MHz, CDCl3, δ) of C12 solid lipid. Other lipids decidedly 
look exactly the same with the exception of the broad peak at 1.27 ppm. In increasing 
order of hydrophobicity the lipids peaks are: [C8 lipid] 0.89 (t,6H), 1.27 (s,16H), 2.43 
(t,4H), 4.76 (s,4H), [C10 lipid] 0.89 (t,6H), 1.27 (s,24H), 2.43 (t,4H), 4.76 (s,4H), [C12 
lipid] 0.89 (t,6H), 1.27 (s,32H), 2.43 (t,4H), 4.76 (s,4H), [C14 lipid] 0.89 (t,6H), 1.27 
(s,40H), 2.43 (t,4H), 4.76 (s,4H), [C16 lipid] 0.89 (t,6H), 1.27 (s,48H), 2.43 (t,4H), 
4.76 (s,4H). 
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Scheme C.1. Reaction schematic for synthesis of lipids C8 to C16 
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The sessile contact angle of PBS buffer on each lipid surface was measured to 
establish the relative hydrophobicity differences among the lipids (Figure C.2a. left).  
The hydrophobic nature of each lipid is important for two reasons.  First, lipids with 
insufficient hydrophobicity would be unable to form solid microparticles.  Second, 
significant variability of the lipid hydrophobicity could be used to control the rate of 
drug release from the microparticles in the same way hydrophobicity is used to 
regulate drug release from polymer-based microparticles [40].  The contact angles show 
an increasing trend in hydrophobicity among the lipids, with the series straddling 90°, 
the angle at which surfaces transition from “hydrophilic” to “hydrophobic”.  
 
 
Figure C.2. Left, a) The sessile contact angle with PBS buffer (n=3,p<0.05, ±SEM). 
Columns marked by asterisk (*) are statistically significant compared to the 
subsequent more hydrophobic lipid (i.e.C10 compared to C12). Right, b) Zeta potential 
of lipid microparticles in 1:10 dilutions of PBS:water, (n=3, p<0.05, ±SEM). All lipid 
particle surfaces retain a negative charge. 
 
 The particles are negatively charged as well, likely from hydrolyzed ester groups at 
the surface (Figure C.2b.).  The negative charge is advantageous because very 
hydrophobic particulates are prone to aggregation, but Coulombic charge repulsion 
can facilitate singular particle dispersion with little input energy.   
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Both the mean hydrodynamic and mean aerodynamic particle sizes were 
measured.  The effect of lipid concentration and surfactant concentration on the 
hydrodynamic particle size, with constant stirring rate and temperature, was 
determined by serial variation of both parameters.  The results showed that increasing 
the lipid concentration led to an increase in mean diameter, and increasing the 
surfactant concentration decreases the mean diameter (Table C.2.).  The aerodynamic 
diameters showed particle sizes varying from 8µm to 32µm with minimum calculated 
density of 0.08 to 0.79 g/cm3, suggesting their potential application for pulmonary 
drug delivery since these densities lie within the desired range for favorable deep lung 
deposition 41. 
 
Table C.2. Particle size measurement results using Coulter counter 
 
 
Inspection of surface morphology by SEM supports the hydrodynamic and 
aerodynamic diameter data, revealing porous structures on the surface and throughout 
the matrix (Figure C.3.).  Interestingly, particle porosity is a function of the lipid 
length, with the shorter lipids giving denser particles.  Particles from both C8 and C10 
show a relatively smooth surface compared to C12 through C16.  Additionally, the 
surface structures become more prominent as the lipid chain length increases. 
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Figure C.3. Lipid microparticles morphology as a function of lipid chain length. 
Clockwise from top-left, (A) C8 particle morphology showing a smooth surface 
followed by (B) C10, (C) C12, (D) C14, and (E) C16. Note the increasing porosity with 
increasing lipid chain length. 
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Figure C.4. Left, (a) Encapsulation efficiency measurements for particles containing 
nile red as hydrophobic model drug. Right, (b) Nile red release from lipid 
microparticles. All lipids display slow release for the duration of 24 hours (n=3, 
±SEM). Release rates increase with increasing lipid chain length. 
 
Microparticles containing nile red were successfully fabricated from all lipids 
in the series using the method of spontaneous emulsification.  Encapsulation 
efficiencies exceeded 70% for all lipids (Figure C.4a.).  The in vitro release 
characteristics of lipid microparticles encapsulating nile red, a model for hydrophobic 
drugs, was observed over a 24 hour period at 37 °C.  The microparticles exhibited 
chain length-dependent release behavior, but in an unexpected manner with 
microparticles fabricated from longer chain lipid particles giving faster release kinetics 
(Figure C.4b.).  Based on the SEM images and particle density calculations, it appears 
that this release behavior is governed more strongly by microparticle porosity, and 
subsequently the surface area, than by lipid hydrophobicity.  
However, the observed release kinetics could also be influenced by the 
distribution of the nile red within the microparticle.  To ascertain whether the intra-
particle drug distribution was driving the release behavior from the lipid 
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microparticles, confocal microscopy was used to visualize the spatial deposition of 
nile red within particles of each lipid length (Figure C.5.).  The images show that nile 
red is deposited near the surface for all microparticles, but the interior content 
increases with increasing lipid length, particularly with C16.  These results support the 
premise that microparticle porosity and surface area governs nile red release kinetics 
from the microparticles since greater interior content of the more hydrophobic 
particles would retard nile red release whereas the opposite is observed in Figure 4b. 
 
 
Figure C.5. Model drug distribution within lipid microparticles, clockwise from top-
left, (a) nile red encapsulated C8 particles (b) nile red encapsulated C10 particles, (c) 
nile red encapsulated C12 particles, (d) nile red encapsulated C14 particles, (e) nile red 
encapsulated C16 particles. It is apparent that with increasing lipid chain length the 
hydrophilic model drug distribution moves toward the surface of the particle, whilst 
the hydrophobic model drug remains homogenously distributed.  
 
D. Conclusion 
In conclusion, a family of DHA derived symmetrical lipids with varying 
hydrocarbon chain length were synthesized to systematically analyze how lipid length 
influences microparticle fabrication, microparticle morphology, and drug release 
kinetics.  Our results are somewhat surprising in that the release kinetics of a 
hydrophobic drug model increased with increasing lipid length.  SEM and confocal 
microscopy images, as well as particle density calculations collectively suggest that 
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the microparticle porosity is the primary factor that controls release kinetics, as 
microparticle porosity increases with increasing lipid length.   
E  Liquid hydrophobic matrices for controlled drug delivery 
E. 1.   Materials and methods 
Acetic anhydride, butyric anhydride, hexanoyl anhydride, terahydrofuran, 
pyridine, 1,3-Dihydroxyacetone dimer 97% (DHA), sodium borohydride , anhydrous 
pyridine and rhodamine-B were all obtained from Sigma-Aldrich (Saint Louis, MO) 
and used without further purification. Dichloromethane (DCM), acetone, 
tetrahydrofuran (THF) and diethyl ether were purchased from J.T.Baker (West 
Chester, PA). All reagents and solvents were used as received without additional 
purification  
E.2.  Synthesis and characterization 
Synthesis and characterization of symmetrical diglycerides 
1,3-dihydroxypropan-2-one 1,3-dialkylate 
Symmetrical lipids were synthesized through modification of a previously 
reported method by Bentley and McCrae 39.  The general procedure for short length 
lipids is as follows, using the synthesis of C2 symmetrical lipid as an example: DHA 
(15.0 g, 153 mmole) was stirred in anhydrous pyridine (50 mL) under flow of N2 at 
room temperature, followed by sequential dropwise (1 drop/sec) addition of acetic 
anhydride (50 ml, 453 mmol), in that order.  The mixture was stirred for 1 hrs at room, 
after which all solvents were removed as completely as possible by vacuum 
distillation.  The residue was dissolved in ethyl acetate, and washed with water (1 × 50 
mL), and 3% aqueous hydrochloric acid (1 × 75 mL), and water (1 × 75 mL) and 
dried. Solvent removal by rotoevaporation in vacuo and crystallization with toluene-
hexanes (1:1) resulted in long colorless needles as product.  1H-NMR spectra were 
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recorded at room temperature with a Brucker AF-300 spectrometer operating at 
300.13 MHz, and elemental analyses were obtained through QTI (Whitehouse, NJ).  
A series of symmetrical diglycerides were synthesized via modification of 
previously suggested synthetic routes by Bentley and McCrae [39].  The protocol is as 
follows (for C2 diglyceride as an example), the above synthesized solid lipid (10.0 g) 
was dissolved in a mixture of tetrahydrofuran:water (150:10) and treated portionwise 
with neutral sodium borohydride (2 g) at 5oC.  After 30 minutes excess sodium 
borohydride was destroyed via dropwise addition (1 drop/s) of glacial acetic acid (1 
mL).  The solution was diluted with chloroform, washed with DI-water, and aqueous 
sodium bicarbonate solution, and DI-water and subsequently dried over sodium 
sulfate, scheme E.2.  Finally the solvent was removed by rotary evaporation in vacuo 
to obtain the final diglycerides product.  As mentioned above, 1H-NMR spectra were 
recorded at room temperature with a Brucker AF-300 spectrometer.  Products were 
stored on dry conditions at 4oC until further use. 
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Scheme E.2. Synthesis of symmetrical 1,3-diglycerides 
E.3.  In vitro controlled release of Rhodamine-B 
In vitro release kinetics were determined by dissolving rhodamine-B as a 
model drug in intended lipid, 1-mL of PBS buffer was added to the solution (total 
volume=2 mL).  The oil in water (o/w) biphasic suspension was incubated at 37 °C 
and placed under gentle rotation.  PBS buffer was removed for fluorescence 
measurement after certain time intervals to determine the amount of release, and 
replenished with fresh buffer. Rhodamine-B concentration was measured at λExc=540 
nm and λEm=565 nm and quantified according to a standard curve of rhodamine-B in 
PBS. 
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E.4.  Cytotoxicity 
Cell viability and proliferation in the presence of each diglycerides were 
examined using HeLa cells (Human epithelial carcinoma cell line) that were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% Fetal Bovine serum (FBS) 
and 1% penicillin/streptomycin.  All cells were maintained at 37 oC in a humidified 
atmosphere of 95% air, 5% CO2. Cells were then seeded into 96-well plates at an 
approximate density of 5000 cells per well (25000 cells/ml).  Dilutions of model drug 
that were prepared with dimethyl sulfoxide to avoid phase separation upon addition of 
the drug into the wells were added 24 hrs later.  The cells were incubated with the 
dilutions for 4 hrs, after which the drug dilution was removed and replaced with fresh 
media.  The MTT reagent (20 µL) was added 24 hrs later, cells were incubated with 
the reagent for 1 hr. The concentration of the viable cells in each well was determined 
by UV absorbance at λ=490 nm using a microplate spectrafluorometer.  
F.  Results and discussion 
A series of symmetrical diglyceride were successfully synthesized by using 
wet-THF as a suitable solvent and NaBH4 as a mild reducing agent (Scheme 3).  The 
final diglycerides range from liquid (C2-C8) to waxy solid (C10) at room temperature 
(Table 3).  Physical characterization using thin layer chromatography showed presence 
of 1,3 and 1,2 isomers, the results were confirmed by 1H NMR (300 MHz, CDCl3), 
(Figure F.6).  
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Figure F.1. 1H NMR (300 MHz, CDCl3, δ) of C2 diglyceride. Other diglycerides 
decidedly look exactly the same with the exception of the large peak at 2.21 ppm. The 
peaks for [C2 diglyceride] are 2.20 (m,12H), 2.8 (s,1H), 3.8 (s,1H), 4.10-4.30 (m,4H), 
and 5.10 (p,1H).  
 
Table F.1. Elemental analysis of symmetrical diglycerides 
 
 
The level of hydrophobicity was estimated using via calculations of the 
partition coefficient (LogP) using ChemDraw software (Table F.1.).  Reasons behind 
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estimation of hydrophobicity are two-fold. First, Log P values show whether the 
diglyceride is miscible with water or not.  Second, similar to symmetrical DHA lipids, 
the variation of diglycerides hydrophobicity can be used to regulate the rate of the 
drug release.  
 
 
Figure F.2. Left, a) Release profiles of rhodamine-B from rhodamine-B/diglycerides 
into aqueous phase (PBS buffer). Right, b) Release profiles of rhodamine-B from 
rhodamine-B/diglycerides/PEG(MW~200) into PBS buffer. 
 
The in vitro release characteristics of rhodamine-B dissolved in diglycerides, a model 
for hydrophilic drugs, was observed over an extended period of time at 37 °C.  The 
diglycerides exhibited chain length-dependent release behavior, similar to lipid 
microparticles, more hydrophobic diglycerides namely C8 and C6 released faster than 
less hydrophobic C4 diglyceride.  Additionally, C6 diglyceride formed a double 
interface with the PBS buffer, thus resulting in faster release kinetics compared to 
more hydrophobic C8 diglyceride (Figure F. 2a. -left, Figure F.3.). 
To determine whether the rhodamine-B and diglcyeride interaction was driving 
the release behavior from the lipid microparticles, polyethylene glycol (PEG) with MW 
of 200 was added to the binary heterogeneous mixture under identical conditions to 
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the original experiment.  The results showed that the more hydrophobic diglycerides 
(C8) released faster compared to C6 and C4 diglyceride.  The cumulative release of 
each mixture compared to the binary mixture of drug and diglycerides/PBS buffer was 
higher, up to 10% in case of C8-diglyceride (Figure F.2b. -right).  These results 
support the premise that interactions between the hydrophobic matrix and hydrophilic 
model drug are the main driving forces behind the release kinetics observed in this 
experiment.  
 
Presence of low molecular weight PEG impacts the initial release readings more 
strongly compared to the later ones, mainly because PEG is more miscible with PBS 
buffer rather than the diglycerides (Figure F.2b. -right).  
Lastly, cells treated with free diglycerides showed decreasing viability with 
increasing hydrophobicity (Figure F.4.).  Previously obtained results by Malhi et al. 
and Feldstein et al. showed that free fatty acids induce lipoapoptosis in hepatocyte 
cells (HepG2) 43, presuming that the diglycerides enzymatically degrade into their 
building blocks of fatty acids and dihydroxyacetone, the resulting fatty acids may act 
as cellular toxins and thus cause apoptosis.  According to Feldstein et al. over-
accumulation of fatty acids in non-adipose tissue, will lead to their entry into the 
nonoxidative deleterious pathways causing cell injury and death 44.   
Figure F.4. Cell viability and IC50 after 
the diglycerides treatment 
Figure F.3. Formation of interfaces 
between oily and aqueous layers 
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G. Conclusion 
In conclusion, a family of DHA derived symmetrical lipids and their glyceride 
analogs with varying hydrocarbon chain length were synthesized to systematically 
analyze how lipid length influences drug release kinetics.  Our results are somewhat 
surprising in that the release kinetics of model drugs increased with increasing lipid 
hydrophobicity.  In case of microparticles, SEM and confocal microscopy images, as 
well as particle density calculations collectively suggest that the microparticle porosity 
is the primary factor that controls release kinetics, as microparticle porosity increases 
with increasing lipid length.  As for the diglycerides, the inability to control the 
number of interfaces formed between the oily phase and the aqueous phase complicate 
our efforts for in further understanding the process of release from liquid hydrophobic 
matrices.  In addition, the cytotoxic nature of the diglycerides makes them unsuitable 
for our intended applications of drug delivery. 
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